Markers for early detection of colon cell proliferation disorders
Patent Information
- Application Number
- JP2023537479
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-21
- Filing Date
- 2021-12-14
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2041-12-14
AI Technical Summary
Colorectal cancer (CRC) is a leading cause of cancer-related mortality due to late diagnosis, as current diagnostic tests like colonoscopies are often performed too late, and there is a lack of a universally specific screening test for early detection.
The use of protein profiling methods to identify specific biomarkers in biological samples for early detection of colon cell proliferative disorders, including advanced adenomas and colon cancer, using a panel of proteins such as EGF, FGF-2, FLT3L, fractalkine, and others, combined with machine learning models for classification.
The method provides high specificity and sensitivity for distinguishing between healthy subjects and those with benign colon polyps, advanced adenomas, or colon cancer, enabling early detection and potential treatment to prevent cancer progression.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 128,545, filed December 21, 2020, which is incorporated by reference in its entirety.
[0002] The present disclosure relates to biomarkers and methods for the early detection of colon cell proliferative disorders, including advanced adenomas and colon cancer. [Background technology]
[0003] Colorectal cancer (CRC) is the leading cause of cancer-related mortality in Western countries. Although CRC is one of the best-characterized solid tumors, it is one of the leading causes of death in developed countries due to the lateness of diagnosis. Among other reasons, patients are diagnosed late due to the fact that diagnostic tests such as colonoscopy are performed too late. Deaths from CRC can be prevented by effective and early screening. Summary of the Invention
[0004] The present disclosure provides a method and system directed to protein profiling of biological samples related to CRC detection and disease progression.The research described herein allows for the determination of the presence of specific protein signatures of CRC that indicate the presence of specific biomarkers of colon cell proliferative disorders that may detect colon cell proliferative disorders, stratify patient populations, and classify populations with high specificity and sensitivity using plasma from subjects with colon cell proliferative disorders.
[0005] In one aspect, the present disclosure provides a method for the treatment of cancer, comprising administering to the patient a therapeutically effective amount of ... A predetermined protein panel characteristic of a colon cell proliferative disorder is provided, comprising at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA.
[0006] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6RA, ORM, or a combination thereof.
[0007] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, or a combination thereof.
[0008] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, AGRP, haptoglobin, ANGPTL4, FGF-23, complement component C2, ORM2, FGF-23, MUC-16, EGF, or combinations thereof.
[0009] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, or any combination thereof.
[0010] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, HGFR, THBS2, CA125 (MUC-16), CA19-9, CA15-3 (MUC-1), or any combination thereof.
[0011] In some embodiments, the panel comprises total PSA.
[0012] In some embodiments, the panel is configured to distinguish between healthy subjects, subjects with benign colon polyps, subjects with advanced adenomas, or subjects with colon cancer.
[0013] In some embodiments, the panel is configured to be indicative of advanced adenomas and includes 1) FLT3L, CEACAM5, IL-6RA, and ORM; 2) FLT3L, CEACAM5, IL-6RA, CEA, ORM, IL-8, AGP, IL-1RT2, TNC, and GDF-15; or 3) FLT3L, CEACAM5, IL-6RA, CEA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, AGRP, haptoglobin, ANGPTL4, FGF-23, complement component C2, ORM2, FGF-23, MUC-16, EGF, p00738, or a combination thereof.
[0014] In some embodiments, the panel is configured to be indicative of colorectal cancer and includes proteins selected from the group consisting of: 1) FLT3L, CEACAM5, and IL-6RA; 2) FLT3L, CEACAM5, IL-6RA, IL-8, IL-1RT2, TNC, and combinations thereof; or 3) FLT3L, CEACAM5, IL-6RA, IL-8, AFP, IL-1RT2, TNC, MUC-16, EGF, and combinations thereof.
[0015] In some embodiments, the colon cell proliferative disorder is selected from the group consisting of adenoma (adenomatous polyp), polyposis disorder, Lynch syndrome, sessile serrated adenoma (SSA), advanced adenoma, colorectal dysplasia, colorectal adenoma, colorectal cancer, colon cancer, rectal cancer, colorectal carcinoma, colorectal adenocarcinoma, carcinoid tumor, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), lymphoma, and sarcoma.
[0016] In another aspect, the disclosure provides a classifier configured to distinguish a population of healthy subjects from subjects having a colon cell proliferative disorder, the classifier comprising a set of measurements representing proteins from a predetermined protein panel characteristic of a colon cell proliferative disorder, the set of measurements being obtained from protein expression data of samples of the healthy subjects and samples of the subjects having a colon cell proliferative disorder, the set of measurements being used to generate a set of features corresponding to characteristics of the protein expression data, the set of features being computationally processed using a machine learning or statistical model, the machine learning or statistical model providing a feature vector useful as a classifier capable of distinguishing a population of healthy subjects from subjects having a colon cell proliferative disorder.
[0017] In some embodiments, the predetermined protein panel is selected from the group consisting of EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo The antibody comprises at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA.
[0018] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6RA, ORM, or a combination thereof.
[0019] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, or a combination thereof.
[0020] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, AGRP, haptoglobin, ANGPTL4, FGF-23, complement component C2, ORM2, FGF-23, MUC-16, EGF, or combinations thereof.
[0021] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, or a combination thereof.
[0022] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, HGFR, THBS2, CA125 (MUC-16), CA19-9, CA15-3 (MUC-1), or a combination thereof.
[0023] In some embodiments, the panel comprises total PSA.
[0024] In some embodiments, the classifier is configured to distinguish between healthy subjects, subjects with benign colon polyps, subjects with advanced adenomas, or subjects with colon cancer.
[0025] In some embodiments, the panel is configured to be indicative of advanced adenoma and includes a protein selected from 1) FLT3L, CEACAM5, IL-6RA, ORM, or a combination thereof; 2) FLT3L, CEACAM5, IL-6RA, CEA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, or a combination thereof; or 3) FLT3L, CEACAM5, IL-6RA, CEA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, AGRP, haptoglobin, ANGPTL4, FGF-23, complement component C2, ORM2, FGF-23, MUC-16, EGF, p00738, or a combination thereof.
[0026] In some embodiments, the panel is configured to be indicative of colorectal cancer and includes proteins selected from 1) FLT3L, CEACAM5, IL-6RA, and combinations thereof; 2) FLT3L, CEACAM5, IL-6RA, IL-8, IL-1RT2, TNC; or 3) FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, MUC-16, EGF, and combinations thereof.
[0027] In some embodiments, the colon cell proliferative disorder is selected from the group consisting of adenoma (adenomatous polyp), polyposis disorder, Lynch syndrome, sessile serrated adenoma (SSA), advanced adenoma, colorectal dysplasia, colorectal adenoma, colorectal cancer, colon cancer, rectal cancer, colorectal carcinoma, colorectal adenocarcinoma, carcinoid tumor, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), lymphoma, and sarcoma.
[0028] In another aspect, the present disclosure provides a system including a machine learning model classifier for detecting colon cell proliferative disorders, comprising a computer readable medium comprising a classifier operable to classify a subject based on a predetermined protein panel, and one or more processors for executing instructions stored on the computer readable medium.
[0029] In some embodiments, the system comprises a classifier configured to distinguish a population of healthy subjects from subjects having a colon cell proliferative disorder, the classifier comprising a set of measurements representing proteins from a predetermined protein panel characteristic of a colon cell proliferative disorder, the set of measurements being obtained from protein expression data of samples of healthy subjects and samples of subjects having a colon cell proliferative disorder, the measurements being used to generate a set of features corresponding to characteristics of the protein expression data, the set of features being computationally processed using a machine learning or statistical model, the machine learning or statistical model providing a feature vector useful as a classifier capable of distinguishing a population of healthy subjects from subjects having a colon cell proliferative disorder.
[0030] In some embodiments, the panel includes any of the following: EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo The antibody comprises at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA.
[0031] In some embodiments, the machine learning model is trained using training data obtained from training biological samples, a first subset of the training biological samples identified as corresponding to subjects having a colon cell proliferative disorder and a second subset of the training biological samples identified as corresponding to subjects not having a colon cell proliferative disorder.
[0032]
[0001] In some embodiments, a classifier is provided in a system for detecting colon cell proliferative disorders comprising: a) a computer-readable medium including a classifier operable to classify a subject based on a protein signature panel; and b) one or more processors for executing instructions stored on the computer-readable medium.
[0033] In some embodiments, the system includes a classification circuit configured as a machine learning classifier selected from the group consisting of a deep learning classifier, a neural network classifier, a linear discriminant analysis (LDA) classifier, a quadratic discriminant analysis (QDA) classifier, a support vector machine (SVM) classifier, a random forest (RF) classifier, a K-nearest neighbors classifier, a linear kernel support vector machine classifier, a first or second order polynomial kernel support vector machine classifier, a ridge regression classifier, an elastic net algorithm classifier, a sequential minimal problem optimization algorithm classifier, a naive Bayes algorithm classifier, and a principal component analysis classifier.
[0034] In another aspect, the disclosure provides a method for determining a protein profile of a biological sample containing a protein of interest, comprising: a) obtaining a protein-containing biological sample from a subject; b) EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo measuring the amount of a protein from a predetermined panel of proteins comprising at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, thereby providing a protein profile of the subject; The present invention provides a method comprising:
[0035] In some embodiments, the predetermined panel of proteins comprises FLT3L, CEACAM5, IL-6RA, ORM, or a combination thereof.
[0036] In some embodiments, the predetermined panel of proteins includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, or a combination thereof.
[0037] In some embodiments, the predetermined panel of proteins includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, AGRP, haptoglobin, ANGPTL4, FGF-23, complement component C2, ORM2, FGF-23, MUC-16, EGF, or a combination thereof.
[0038] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, or a combination thereof.
[0039] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, HGFR, THBS2, CA125 (MUC-16), CA19-9, CA15-3 (MUC-1), or a combination thereof.
[0040] In some embodiments, the panel comprises total PSA.
[0041] In some embodiments, the protein profile is associated with a colon cell proliferative disorder and provides a classification of subjects with a colon cell proliferative disorder.
[0042] In some embodiments, the subject's biological sample is selected from the group consisting of bodily fluids, stool, colonic discharge, urine, plasma, serum, whole blood, isolated blood cells, cells isolated from blood, tissue biopsy, and combinations thereof.
[0043] In some embodiments, the colon cell proliferative disorder is selected from the group consisting of adenoma (adenomatous polyp), polyposis disorder, Lynch syndrome, sessile serrated adenoma (SSA), advanced adenoma, colorectal dysplasia, colorectal adenoma, colorectal cancer, colon cancer, rectal cancer, colorectal carcinoma, colorectal adenocarcinoma, carcinoid tumor, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), lymphoma, and sarcoma.
[0044] In some embodiments, the methods further comprise treating the subject with a surgery and / or a therapeutic agent based on the subject's protein profile.
[0045] In another aspect, the disclosure provides a method of detecting a colon cell proliferative disorder in a subject, comprising: a) obtaining a protein-containing biological sample from a subject; b) EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo measuring the amount of a protein from a predetermined protein panel comprising at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, thereby providing a protein profile of the subject; c) computing the protein profile into a machine learning model trained to distinguish between healthy subjects and subjects with a colon cell proliferative disorder to provide an output value related to the presence or absence of a colon cell proliferative disorder, thereby indicating the presence or absence of a colon cell proliferative disorder in the subject; The present invention provides a method comprising:
[0046] In some embodiments, the predetermined panel of proteins comprises FLT3L, CEACAM5, IL-6RA, ORM, or a combination thereof.
[0047] In some embodiments, the predetermined panel of proteins includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, or a combination thereof.
[0048] In some embodiments, the predetermined panel of proteins includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, AGRP, haptoglobin, ANGPTL4, FGF-23, complement component C2, ORM2, FGF-23, MUC-16, EGF, or a combination thereof.
[0049] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, or a combination thereof.
[0050] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, HGFR, THBS2, CA125 (MUC-16), CA19-9, CA15-3 (MUC-1), or a combination thereof.
[0051] In some embodiments, the panel comprises total PSA.
[0052] In some embodiments, the protein profile is associated with a colon cell proliferative disorder and provides a classification of subjects with a colon cell proliferative disorder.
[0053] In some embodiments, the subject's biological sample is selected from the group consisting of bodily fluids, stool, colonic discharge, urine, plasma, serum, whole blood, isolated blood cells, cells isolated from blood, tissue biopsy, and combinations thereof.
[0054] In some embodiments, the colon cell proliferative disorder is selected from the group consisting of adenoma (adenomatous polyp), polyposis disorder, Lynch syndrome, sessile serrated adenoma (SSA), advanced adenoma, colorectal dysplasia, colorectal adenoma, colorectal cancer, colon cancer, rectal cancer, colorectal carcinoma, colorectal adenocarcinoma, carcinoid tumor, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), lymphoma, and sarcoma.
[0055] In some embodiments, the method further comprises administering a treatment to the subject based on the detected colon cell proliferative disorder, hi some embodiments, the treatment comprises chemotherapy, radiation therapy, immunotherapy, or surgery.
[0056] In another aspect, a method is provided for monitoring minimal residual disease in a subject previously treated for a disease, the method comprising: a) EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo determining a protein profile of the subject's biological sample using a panel of at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, thereby generating a baseline protein status; b) determining a protein profile of a biological sample obtained from the subject at one or more time points after generation of the baseline protein status, thereby generating a current protein status; c) determining the difference between the baseline protein status and the current protein status, thereby detecting a change in minimal residual disease in the subject; Includes.
[0057] In some embodiments, the minimal residual disease is selected from the group consisting of response to treatment, tumor burden, post-surgery residual tumor, recurrence, secondary screening, primary screening, and cancer progression. In some embodiments, the method further comprises administering a treatment to the subject based on the detected change in minimal residual disease in the subject. In some embodiments, the treatment comprises chemotherapy, radiation therapy, immunotherapy, or surgery. The treatment may be selected (e.g., from among a plurality of possible treatment options) and administered to the subject based at least in part on the subject's protein profile and / or a set of biological traits of the subject. The biological trait may be a measurement, a diagnosis, a prognosis, or a prediction (e.g., determined using a trained machine learning classifier).
[0058]
[0003] In some embodiments, the biological trait comprises a malignancy.
[0004] In some embodiments, the biological trait comprises a cancer type. In some embodiments, the biological trait comprises a cancer stage. In some embodiments, the biological trait comprises a cancer classification. In some embodiments, the cancer classification comprises a cancer grade. In some embodiments, the cancer classification comprises a histological classification. In some embodiments, the biological trait comprises a metabolic profile. In some embodiments, the biological trait comprises a mutation. In some embodiments, the mutation is a disease-associated mutation. In some embodiments, the biological trait comprises a clinical outcome. In some embodiments, the biological trait comprises a drug response.
[0059] In another aspect, a method is provided for determining a subject's response to a treatment, the method comprising: a) EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo determining a protein profile of the subject's biological sample using a panel of at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, thereby generating a baseline protein status; b) determining a protein profile of a biological sample obtained from the subject at one or more time points after generation of the baseline protein status, thereby generating a current protein status; c) determining the difference between the baseline protein status and the current protein status, thereby determining the subject's response to treatment; Includes.
[0060] In some embodiments, the method further comprises administering a treatment to the subject based on the subject's determined response to the treatment, hi some embodiments, the treatment comprises chemotherapy, radiation therapy, immunotherapy, or surgery.
[0061] In another aspect, a method is provided for monitoring tumor burden in a subject, the method comprising: a) EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo determining a protein profile of the subject's biological sample using a panel of at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, thereby generating a baseline protein status; b) determining a protein profile of a biological sample obtained from the subject at one or more time points after generation of the baseline protein status, thereby generating a current protein status; c) determining the difference between the baseline protein status and the current protein status, thereby monitoring the subject's tumor burden; Includes.
[0062] In some embodiments, the method further comprises administering a treatment to the subject based on the subject's tumor burden, hi some embodiments, the treatment comprises chemotherapy, radiation therapy, immunotherapy, or surgery.
[0063] In another aspect, a method is provided for detecting post-operative residual tumor in a subject, the method comprising: a) EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo determining a protein profile of the subject's biological sample using a panel of at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, thereby generating a baseline protein status; b) determining a protein profile of a biological sample obtained from the subject at one or more time points after generation of the baseline protein status, thereby generating a current protein status; c) determining the difference between the baseline protein status and the current protein status, thereby detecting post-operative residual tumor in the subject; Includes.
[0064] In some embodiments, the method further comprises administering a treatment to the subject based on the subject's detected post-operative residual tumor, hi some embodiments, the treatment comprises chemotherapy, radiation therapy, immunotherapy, or surgery.
[0065] In another aspect, a method is provided for detecting recurrence in a subject, the method comprising: a) EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo determining a protein profile of the subject's biological sample using a panel of at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, thereby generating a baseline protein status; b) determining a protein profile of a biological sample obtained from the subject at one or more time points after generation of the baseline protein status, thereby generating a current protein status; c) determining the difference between the baseline protein status and the current protein status, thereby detecting relapse in the subject; Includes.
[0066] In some embodiments, the method further comprises administering a treatment to the subject based on the subject's detected recurrence, hi some embodiments, the treatment comprises chemotherapy, radiation therapy, immunotherapy, or surgery.
[0067] In another aspect, a method is provided for performing a secondary screen based at least in part on the protein profile of the subject.
[0068] In another aspect, a method is provided for performing a primary screen based at least in part on a protein profile of a subject.
[0069] In another aspect, a method is provided for monitoring cancer progression in a subject, the method comprising: a) EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo determining a protein profile of the subject's biological sample using a panel of at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, thereby generating a baseline protein status; b) determining a protein profile of a biological sample obtained from the subject at one or more time points after generation of the baseline protein status, thereby generating a current protein status; c) determining the difference between the baseline protein status and the current protein status, thereby monitoring the subject's cancer progression; Includes.
[0070] In some embodiments, the method further comprises administering a treatment to the subject based on the subject's monitored cancer progression, hi some embodiments, the treatment comprises chemotherapy, radiation therapy, immunotherapy, or surgery.
[0071] In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with at least about 25% sensitivity. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with at least about 30% sensitivity. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with at least about 35% sensitivity. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with at least about 40% sensitivity. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with at least about 50% sensitivity. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with at least about 60% sensitivity. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with at least about 70% sensitivity. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with at least about 80% sensitivity. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with at least about 90% sensitivity. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with at least about 95% sensitivity.
[0072] In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a positive predictive value (PPV) of at least about 5%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a positive predictive value (PPV) of at least about 10%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a positive predictive value (PPV) of at least about 15%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a positive predictive value (PPV) of at least about 20%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a positive predictive value (PPV) of at least about 25%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a positive predictive value (PPV) of at least about 30%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a positive predictive value (PPV) of at least about 40%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a positive predictive value (PPV) of at least about 50%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a positive predictive value (PPV) of at least about 60%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a positive predictive value (PPV) of at least about 70%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a positive predictive value (PPV) of at least about 80%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a positive predictive value (PPV) of at least about 90%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a positive predictive value (PPV) of at least about 95%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a positive predictive value (PPV) of at least about 99%.
[0073] In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a negative predictive value (NPV) of at least about 40%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a negative predictive value (NPV) of at least about 50%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a negative predictive value (NPV) of at least about 60%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a negative predictive value (NPV) of at least about 70%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a negative predictive value (NPV) of at least about 80%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a negative predictive value (NPV) of at least about 90%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a negative predictive value (NPV) of at least about 95%. In some embodiments, the protein profile indicates the presence or susceptibility of colorectal cancer with a negative predictive value (NPV) of at least about 99%.
[0074] In some embodiments, the trained algorithm determines the presence or susceptibility of the subject to colon cancer using an area under the curve (AUC) of at least about 0.50. In some embodiments, the trained algorithm determines the presence or susceptibility of the subject to colon cancer using an area under the curve (AUC) of at least about 0.60. In some embodiments, the trained algorithm determines the presence or susceptibility of the subject to colon cancer using an area under the curve (AUC) of at least about 0.70. In some embodiments, the trained algorithm determines the presence or susceptibility of the subject to colon cancer using an area under the curve (AUC) of at least about 0.80. In some embodiments, the trained algorithm determines the presence or susceptibility of the subject to colon cancer using an area under the curve (AUC) of at least about 0.90. In some embodiments, the trained algorithm determines the presence or susceptibility of the subject to colon cancer using an area under the curve (AUC) of at least about 0.95. In some embodiments, the trained algorithm determines the presence or susceptibility of the subject to colon cancer using an area under the curve (AUC) of at least about 0.99.
[0075] In some embodiments, the method further comprises presenting the electronic device or report to a user, hi some embodiments, the user is a subject, individual, or patient.
[0076] In some embodiments, the method further comprises determining the likelihood of the presence or susceptibility to colorectal cancer in the subject, individual, or patient.
[0077] In some embodiments, the trained algorithm (e.g., machine learning model or classifier) comprises a supervised machine learning algorithm or a semi-supervised machine learning algorithm. In some embodiments, the supervised machine learning algorithm comprises a deep learning algorithm, a support vector machine (SVM), a neural network, or a random forest.
[0078] In some embodiments, the method further includes providing a therapeutic intervention to the subject, or administering to the subject a treatment, such as a therapeutic intervention (e.g., chemotherapy, radiation therapy, immunotherapy, or surgery) for treating a patient with colorectal cancer based at least in part on the protein profile or analysis.
[0079] In some embodiments, the method further includes a step of monitoring the presence or susceptibility of colorectal cancer, comprising assessing the presence or susceptibility of colorectal cancer in the subject at a plurality of time points, wherein the assessing is based at least in part on the presence or susceptibility of colorectal cancer determined at each of the plurality of time points.
[0080] In some embodiments, differences in the assessment of the presence or susceptibility of colorectal cancer in the subject at the multiple time points are indicative of one or more clinical indications selected from the group consisting of: (i) a diagnosis of the presence or susceptibility of colorectal cancer in the subject; (ii) a prognosis of the presence or susceptibility of colorectal cancer in the subject; and (iii) the effectiveness or ineffectiveness of a treatment strategy for treating the presence or susceptibility of colorectal cancer in the subject.
[0081] In some embodiments, the method further comprises stratifying the subject's colon cancer by using a trained algorithm that determines the subtype of the subject's colon cancer from among multiple distinct subtypes or stages of colon cancer.
[0082] Another aspect of the present disclosure provides a non-transitory computer-readable medium comprising machine-executable code that, when executed by one or more computer processors, implements any of the methods described above or anywhere herein.
[0083] Another aspect of the present disclosure provides a system including one or more computer processors and a computer memory coupled thereto, the computer memory including machine executable code that, upon execution by the one or more computer processors, implements any of the methods described above or elsewhere herein.
[0084] Another aspect of the present disclosure provides a system comprising: a) a computer readable medium comprising a classifier for distinguishing a population of subjects having a colon cell proliferative disorder from subjects not having a colon cell proliferative disorder based on a protein signature panel using a machine learning model; and b) one or more processors for executing instructions stored on the computer readable medium.
[0085] Further aspects and advantages of the present disclosure will become readily apparent to those skilled in the art from the following detailed description, in which only exemplary embodiments of the present disclosure have been shown and described. As will be seen from the following description, the present disclosure may be in other and different embodiments, and its several details are capable of modification in various obvious respects, all without departing from the present disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.
[0086] Incorporation by Reference All publications, patents, and patent applications mentioned herein are incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually incorporated by reference herein. To the extent that the publications and patents or patent applications incorporated by reference conflict with the disclosure contained herein, the present specification is intended to supersede and / or take precedence over such conflicting material. [Brief description of the drawings]
[0087] Examples of the present disclosure are described, by way of example only, with reference to the accompanying drawings. The novel features of the invention are set forth with particularity in the appended claims. The features and advantages of the present invention will be better understood by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also referred to herein as "Figures" and "FIGs.") in which:
[0088] [Figure 1] FIG. 1 provides an illustration of a computer system that is programmed or otherwise configured with machine learning models and classifiers to implement the methods provided herein. [Diagram 2] Provides visualization of protein-wise percentiles calculated on single analyte protein data of all available targets in a protein marker dataset. [Diagram 3] We provide visualization of metrics from single-assay protein analysis (left panel) and multi-assay additivity analysis (right panel). The 2.1 list consists of proteins that meet two criteria. The first criterion is proteins that meet maximum and median thresholds of percentile metrics. The second criterion is proteins that pass usage and performance thresholds defined by additivity. The 2.2 list consists of the intersection of proteins found when taking the top 25 proteins by rank for maximum and median of percentile metrics. [Figure 4] We provide ROC curves showing the classification performance of the 53 features for CRC vs. NEG on the discovery data, where all data was used for feature selection but model weights were defined within cross-validation (there was no true holdout in this performance). [Diagram 5] We provide ROC curves showing the classification performance of the 53 features for AA vs. NEG on the discovery data, where all data was used for feature selection but model weights were defined within cross-validation (there was no true holdout in this performance). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0089] While various embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous modifications, changes, and substitutions may be apparent to those skilled in the art without departing from the invention. It is understood that various alternatives to the embodiments of the invention described herein may be utilized.
[0090] CRC is the leading cause of cancer-related mortality in Western countries. Although it is one of the best-characterized solid tumors, CRC is one of the leading causes of death in developed countries due to the lateness of diagnosis. Among other reasons, late patient diagnosis is due to the fact that diagnostic tests such as colonoscopy are performed too late. Deaths from CRC can be prevented by effective screening. Currently, there is no universal specific screening test or panel that is useful in directing clinical decision-making. Cancer screening and monitoring improves survival outcomes, since early detection can eliminate cancer before it grows and metastasizes. In CRC, for example, colonoscopy plays a role in improving early detection. Unfortunately, patient compliance is low and screening is performed with less than the recommended regularity due to the invasiveness of the procedure. The implementation of non-invasive and simpler diagnostic methods that allow early detection of colorectal neoplasms could be based on identifying proteins detectable in serum or plasma. Non-invasive approaches could be the basis for more adapted and earlier screening tests for colorectal neoplasms.
[0091] Recent studies support the existence of tumor-associated antigens in patients with cancer. Because tumor formation is associated with changes in the structure or expression of self-proteins in tumor cells, these changes may serve as potential immunological markers of cancer.
[0092] The presence of cancer and tumors in humans is also associated with the presence of proteins in the serum of patients with cancer.Proteins can be detected at the early stage of the disease, even before cancer can be detected by other techniques, indicating the potential of these proteins as biomarkers of the disease.These proteins can either be affected by changes in expression level, isolated mutations, or can be abnormally folded, overexpressed, abnormally glycosylated, or can be truncated or abnormally degraded.
[0093] Thus, protein biomarkers may allow for simple, effective, and non-invasive methods to diagnose colon neoplasia, classify colon neoplasia at various stages (such as adenoma or tumor progression), prognose disease progression, evaluate disease response to treatment, and detect recurrence or dissemination of colon neoplasia. The diagnostic potential of proteins associated with colon neoplasia may aid in early detection, diagnosis, and prognosis of colon neoplasia.
[0094] The present disclosure generally relates to cancer detection and disease monitoring. In particular, the present disclosure relates to detection of cancer-associated proteins and disease monitoring in colon cell proliferative disorders, such as early stage colon cancer. In particular, circulating protein signature panels and their use are provided for identifying human subjects who have or are at risk of developing colon cell proliferative disorders, such as colorectal cancer (CRC) and / or colorectal adenoma (CA), e.g., advanced colorectal adenoma (AA). Further disclosed herein are tumor-associated proteins in human subjects that indicate the presence or high risk of developing colon cell proliferative disorders, for example, when the subject has colonic lesions.
[0095] Some embodiments of the present disclosure provide differentially abundant proteins in samples of subjects with colon cell proliferative disorder or at high risk of developing colon cell proliferative disorder compared to corresponding samples of subjects without colon cell proliferative disorder or at low risk of developing colon cell proliferative disorder.In some embodiments, subjects with high risk of developing colon cell proliferative disorder and subjects with low risk of developing colon cell proliferative disorder each have non-invasive precursor lesions (hereinafter colon lesions) occurring in the colon mucosa.Proteins present in different abundances in samples of healthy subjects and subjects with colon cell proliferative disorder can be used as biomarkers for the diagnosis, treatment, and / or prevention of colon cell proliferative disorder.
[0096] In some embodiments, the method further comprises comparing the protein profile of the subject's biological sample to a database of reference protein profiles from healthy subjects and determining that the subject has an increased risk of having a colon cell proliferative disorder based at least in part on measuring a change in protein expression levels of at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50% relative to the reference protein profile.
[0097] Machine learning approaches can be used to characterize protein data from biological samples to identify a panel of informative proteins. The identified panel of informative proteins for colon cell proliferative disorders can be useful for training a classifier model that is useful for distinguishing samples from healthy subjects from samples from subjects with colon cell proliferative disorders.
[0098] To identify proteins useful for the methods and classifiers described herein, plasma from subjects with colon cell proliferative disorders and from subjects without colon cell proliferative disorders (control or reference plasma) was examined with the goal of identifying a signature panel of proteins that are produced by or specifically expressed in patients with colon cell proliferative disorders in response to colon cell proliferative disorders. To this end, plasma from patients with colon cell proliferative disorders and control plasma were assayed for protein expression to identify biomarkers.
[0099] The proteins identified herein can be used to identify subjects with colon cell proliferative disorders to distinguish them from subjects without colon cell proliferative disorders, to identify subjects at high risk of developing colon cell proliferative disorders to distinguish them from subjects at low risk of developing colon cell proliferative disorders, or to identify subjects with precursor lesions of colon cell proliferative disorders. Thus, these proteins can be used as ancillary tools to guide decisions regarding monitoring, treatment, and management of colon cell proliferative disorders.
[0100] Other specific embodiments of the present disclosure provide a machine learning model classifier trained on the proteins described herein expressed in plasma samples of healthy subjects and plasma samples of subjects with colon cell proliferative disorders. Training the machine learning model provides a classifier with a set of predefined protein biomarkers ("protein panel" or "signature panel") useful for classifying healthy subjects or subjects with colon cell proliferative disorders. In one example, a method is provided for a blood-based minimally invasive protein assay that can be used on subjects with colonic lesions to assess histological severity. In another embodiment, proteins indicative of colon cell proliferative disorders are detected in acellular samples of subjects. Subject body fluid samples, such as whole blood, plasma, or serum, contain acellular molecules such as proteins. Thus, provided herein are proteins that can be used to distinguish between the presence or absence of colon cell proliferative disorders, high-risk or low-risk colonic lesions that require treatment, such as surgical resection, immunotherapy, radiation, or chemotherapy, and to identify low-risk colonic lesions that can be monitored. Monitoring and confirming the presence of a colon cell proliferative disorder or lesion can be performed, for example, by colonoscopy, ultrasound, MM, or CT scan.
[0101] In some embodiments, disclosed herein are panels of predefined plasma protein biomarkers for use in the early detection of colon cell proliferative disorders and for the early detection of CRC. The predefined protein panels can be used in classifiers that indicate cell proliferative disorders such as advanced adenoma or colon cancer.
[0102] In other embodiments, methods relating to detection, diagnosis, and treatment are disclosed herein. Patient plasma can be screened for a predefined panel of proteins as indicative of a proliferative disorder of the colon.
[0103] Described herein is a method for screening or identifying subjects with or at risk of having colon cell proliferative disorder based on the expression profile or abundance of proteins that are upregulated or overexpressed in subjects suffering from colon cell proliferative disorder.Described herein further is a method for obtaining data useful for diagnosing colon cell proliferative disorder in subjects, for example, human subjects.
[0104] The colon cell proliferative disorder may be at any tumor stage (e.g., TX, TO, Tis, T1, T2, T3, T4), any regional lymph node or distant metastatic stage (e.g., NX, N0, N1, M0, M1), any stage (e.g., stage 0 (Tis, N0, M0), stage IA (T1, N0, M0), stage IIA (T3, N0, M0), stage IIB (T1-3, N1, M0), stage III (T4, any N, M0), or stage IV (any T, any N, M1)), resectable, locally advanced (unresectable), or metastatic.
[0105] Current screening tools may face challenges due to false positive and false negative results, as well as specificity and sensitivity. An ideal cancer screening tool would have a high positive predictive value (PPV), which minimizes unnecessary investigations (low false positives) but detects the majority of cancers (low false negatives). Another important compromise is "detection sensitivity," which differs from test sensitivity, which is the lower limit of tumor detection based on size. Allowing tumors to grow large enough to release circulating tumor markers at detectable levels would defeat the purpose of early detection and prevention of cancer progression. Thus, the present disclosure addresses the need for a sensitive and effective blood-based screen for early diagnosis of colorectal cancer.
[0106] Detection of circulating tumor DNA, also referred to as "liquid biopsy", allows for the detection and informative investigation of tumors in a non-invasive manner. Identification of tumor-specific mutations in these liquid biopsies can be used to diagnose, for example, colon, breast, and prostate cancer. However, due to the high background of normal (i.e., non-tumor-derived) DNA present in the circulation, these techniques can be limited in sensitivity. Thus, there remains a need for more sensitive and specific screening tools to detect early or low tumor burden colorectal cancer tumor markers for recurrence screening and primary screening of risk populations. Circulating proteins against tumor-associated antigens provide another source of informative biomarkers in liquid biopsy samples that can be used in the machine learning models described herein.
[0107] The present disclosure provides a method and system for profiling the circulating proteins related to colon cell proliferation disorder and its progression, such as colon cancer.The proteins that indicate the presence of colon cell proliferation disorder or high risk of developing colon cell proliferation disorder can be used to diagnose, treat or prevent the progression of colon cell proliferation disorder as early as possible, for example, when the subject has only colon lesion.Further provided herein are kits and methods for diagnosing colon cell proliferation disorder or assessing the risk of developing colon cell proliferation disorder in a subject, especially when the subject has colon lesion.
[0108] In one aspect, provided herein is a method of using a panel of proteins that is useful for distinguishing subject samples based on disease state.In another aspect, provided herein is a method, assay, and kit that uses a panel of proteins to detect, distinguish, and distinguish colon cell proliferation disorder.Non-limiting examples of colon cell proliferation disorder include adenoma (adenomatous polyp), polyposis disorder, Lynch syndrome, sessile serrated adenoma (SSA), advanced adenoma, colorectal dysplasia, colorectal adenoma, colorectal cancer, colon cancer, rectal cancer, colorectal carcinoma, colorectal adenocarcinoma, carcinoid tumor, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), lymphoma, and sarcoma.
[0109] In some embodiments, the methods involve the use of one or more proteins selected as markers for differentiation, detection, and distinction of colon cell proliferative disorders.
[0110] definition As used in this specification and claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. For example, the term "nucleic acid" includes a plurality of nucleic acids, including mixtures thereof.
[0111] As used herein, the term "subject" generally refers to an entity or medium for which there is genetic information that can be tested or detected. The subject may be a person, an individual, or a patient. The subject may be a vertebrate, such as a mammal. Non-limiting examples of mammals include humans, monkeys, livestock animals, sport animals, rodents, and pets. The subject may be a person who has cancer or is suspected of having cancer. The subject may exhibit symptoms indicative of the subject's health, physiological condition, or disease, such as the subject's cancer or other disease, disorder, or illness. Alternatively, the subject may be asymptomatic with respect to such health or physiological condition or disease.
[0112] As used herein, the term "sample" generally refers to a biological sample obtained or derived from one or more subjects. A biological sample may be a cell-free or substantially cell-free biological sample, or may be processed or fractionated to generate a cell-free biological sample. For example, a cell-free biological sample may include cell-free ribonucleic acid (cfRNA), cell-free deoxyribonucleic acid (cfDNA), cell-free fetal DNA (cffDNA), proteins, antibodies, plasma, serum, urine, saliva, amniotic fluid, and derivatives thereof. A cell-free biological sample may be obtained or derived from a subject using an ethylenediaminetetraacetic acid (EDTA) collection tube, a cell-free RNA collection tube (e.g., Streck® Complete BCT®), or a cell-free DNA collection tube (e.g., Streck® Cell-Free DNABCT®). A cell-free biological sample may be derived from a whole blood sample by fractionation (e.g., by differential centrifugation). A biological sample or its derivative may include cells. For example, the biological sample can be a blood sample or a derivative thereof (eg, blood or a drop of blood collected by a collection tube).
[0113] As used herein, the term "acellular sample" generally refers to a biological sample that is substantially devoid of intact cells. An acellular sample may be derived from a biological sample that is itself substantially devoid of cells, or from a sample from which cells have been removed. Non-limiting examples of acellular samples include those derived from blood, serum, plasma, urine, semen, sputum, feces, ductal exudate, lymph, and recovered lavage.
[0114] As used herein, the term "colon cell proliferative disorder" generally refers to a disorder or disease involving unregulated or abnormal proliferation of cells in the colon or rectum. Non-limiting examples of colon cell proliferative disorders include adenoma (adenomatous polyp), polyposis disorder, Lynch syndrome, sessile serrated adenoma (SSA), advanced adenoma, colorectal dysplasia, colorectal adenoma, colorectal cancer, colon cancer, rectal cancer, colorectal carcinoma, colorectal adenocarcinoma, carcinoid tumor, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), lymphoma, and sarcoma. As used herein, the abbreviation "CRC" is used to identify a biological sample from a subject diagnosed with colorectal cancer. As used herein, the abbreviation "AA" is used to identify a sample from a subject diagnosed with at least one advanced adenoma. As used herein, the abbreviation "NAA" is used to identify a sample from a subject diagnosed with a colorectal tumor that is benign and not an advanced adenoma or colorectal cancer.
[0115] As used herein, the term "colon cancer" refers to a medical condition generally characterized by cancer of cells of the intestinal tract below the small intestine (i.e., the large intestine (colon), e.g., the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum).
[0116] As used herein, the term "colorectal adenoma" generally refers to adenomas of the colon, also called adenomatous polyps, which are benign and precancerous stages of colorectal cancer. Colorectal adenomas may indicate an increased risk of progression to colorectal cancer.
[0117] As used herein, the term "advanced colorectal adenoma" generally refers to an adenoma that is at least 10 mm in size or has histologically high grade dysplasia or greater than 20% villous component.
[0118] As used herein, the terms "at risk of developing a colon cell proliferative disorder" or "high risk of developing a colon cell proliferative disorder" generally refer to a subject who is at high risk of developing a colon cell proliferative disorder in the near future compared to a subject who does not have a colon cell proliferative disorder or a subject who is at low risk of developing a colon cell proliferative disorder in the near future. As used herein, the term "near future" refers to a period of about 1 month to about 2 years, about 6 months to about 18 months, or about 1 year.
[0119] As used herein, the terms "type" and "subtype" of cancer are generally used relatively herein, such that a "type" of cancer, such as breast cancer, may be a "subtype" based on, for example, stage, morphology, histology, gene expression, receptor profile, mutation profile, aggressiveness, prognosis, and malignant characteristics. Similarly, "type" and "subtype" may be applied at a finer level, for example, to differentiate a histological "type" into "subtypes" defined according to, for example, mutation profile or gene expression. Cancer "stage" is also used to refer to the classification of cancer types based on histological and pathological features associated with disease progression.
[0120] The term "neoplasm" generally refers to any new and abnormal growth of tissue. Thus, a neoplasm may be a premalignant or malignant neoplasm. The term "neoplasm-specific marker" refers to any biological material that can be used to indicate the presence of a neoplasm. Examples of biological material include, but are not limited to, nucleic acids, polypeptides, carbohydrates, fatty acids, cellular components (e.g., cell membranes and mitochondria), and whole cells. The term "colon neoplasm-specific marker" refers to any biological material that can be used to indicate the presence of a colon neoplasm (e.g., a premalignant colon neoplasm or a malignant colon neoplasm).
[0121] As used herein, the term "healthy" generally refers to a subject that does not have a colon cell proliferative disorder. Health is a dynamic state, but as used herein, the term refers to a pathological state of a subject that lacks the disease state referenced in a particular description. In one example, when referring to a signature panel that can classify subjects with colon cancer, a healthy individual, healthy sample, or sample of a healthy individual refers to an individual that lacks colon cancer (CRC), advanced adenoma (AA), or benign adenoma (NAA). As used herein, the abbreviation "NAA" is used to identify samples from individuals that have been evaluated as negative for colon tumors, and thus, in some embodiments, samples identified as NAA are included in the healthy sample group. As used herein, although other diseases or health conditions may be present in the subject, the term "healthy" indicates the absence of the disease being described for the purpose of comparison or classification between subjects with and those lacking the disease state being discussed.
[0122] The term "minimal residual disease" or "MRD" generally refers to a small number of cancer cells in a subject's body after cancer treatment. MRD testing can be performed to determine the effectiveness of cancer treatment and to guide further treatment plans.
[0123] As used herein, the term "screening" generally refers to the examination or testing of a population of subjects at risk for colorectal cancer or colorectal adenoma, for the purpose of identifying healthy subjects from those with undiagnosed colorectal cancer or colorectal adenoma or those at high risk for the above indications.
[0124] As used herein, the term "minimally invasive biological sample" or "non-invasive sample" generally refers to any sample taken from a patient's body without the need for any equipment other than a fine needle used to obtain blood from the subject. In some embodiments, a minimally invasive biological sample includes a blood, serum, or plasma sample.
[0125] As used herein, the term "upregulated" or "overexpressed" generally refers to an increase in expression level of at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150%, or greater than 150% relative to a given "threshold" or "cutoff value."
[0126] As used herein, the term "threshold" or "cutoff value," when referring to an expression level, generally refers to a reference expression level that indicates that if a subject's expression level is above the threshold or cutoff or reference level, the subject is likely to be afflicted with colorectal cancer or colorectal adenoma with a given sensitivity and specificity.
[0127] As used herein, the term "kit" is not limited to any particular device, but includes any device suitable for implementing the systems and methods of the present disclosure, such as, but not limited to, a microarray, a bioarray, a biochip, a biochip array, or a bead-based assay.
[0128] Assay of samples Acellular biological sample can be obtained from or derived from human subject.Acellular biological sample can be stored before processing under various storage conditions, such as different temperatures (e.g., at room temperature, under refrigerated or frozen conditions, e.g., at 25°C, 4°C, -18°C, -20°C or -80°C) or different suspensions (e.g., EDTA collection tube, cell-free RNA collection tube or cell-free DNA collection tube).
[0129] The acellular biological sample can be from a subject that has cancer, a subject suspected of having cancer, or a subject that does not have or is not suspected of having cancer.
[0130] Acellular biological samples may be obtained before and / or after treatment of a subject with cancer. Acellular biological samples may be from a subject during treatment or treatment regimen. Multiple acellular biological samples may be obtained from a subject to monitor the effects of treatment over time. Acellular biological samples may be taken from subjects known or suspected to have cancer where a definitive positive or negative diagnosis is not available via clinical trials. Samples may be taken from subjects suspected of having cancer. Acellular biological samples may be taken from subjects experiencing unexplained symptoms such as fatigue, nausea, weight loss, aches and pains, weakness, or bleeding. Acellular biological samples may be taken from subjects with the described symptoms. Acellular biological samples may be taken from subjects at risk of developing cancer due to factors such as family history, age, hypertension or prehypertension, diabetes or prediabetes, overweight or obesity, environmental exposures, lifestyle risk factors (e.g., smoking, alcohol intake, or drug use), or the presence of other risk factors.
[0131] A cell-free biological sample may contain one or more analytes that can be assayed, such as cell-free ribonucleic acid (cfRNA) molecules suitable for assaying to generate transcriptomic data, cell-free deoxyribonucleic acid (cfDNA) molecules suitable for assaying to generate genomic data, protein molecules suitable for assaying to generate proteomic data, or mixtures or combinations thereof.
[0132] After obtaining the acellular biological sample from the subject, the acellular biological sample can be processed to generate a dataset indicative of the subject's colon cell proliferative disorder. For example, the presence, absence, or quantitative evaluation of protein molecules in the acellular biological sample in a panel of proteins. Processing the subject's acellular biological sample can include (i) exposing the acellular biological sample to conditions sufficient to isolate, enrich, or extract a plurality of proteins, and (ii) assaying the plurality of protein molecules to generate a dataset.
[0133] The biological sample may be directly used in an assay to detect one or more proteins to generate a protein profile of the sample. In some embodiments, the biological sample may be enriched for proteins prior to the assay (e.g., using protein-conjugated microbeads). In some embodiments, the biological sample is a plasma sample and is protein enriched. The biological sample may be assayed using a variety of laboratory methodologies to determine the presence and / or concentration or level of one or more proteins in the biological sample. In some embodiments, such approaches may include, but are not limited to, mass spectrometry, protein microarrays, high density protein microarrays such as CDI proteome arrays, ELISA, Meso Scale Discovery (e.g., Pacific Biolabs), bead-based immunoassays (e.g., Luminex® magnetic bead-based capture assays), secondary fluorescent antibody assays, DNA-antibody conjugates or antibody-metal conjugates (e.g., mass cytometry, CyTOF), HD-X™ and SR-X™ Ultra-Sensitive Biomarker Detection Systems (e.g., Quanterix®), aptamer-based oligohybridization MEMS (e.g., Somalogic), flow cytometry, FirePlex® particle technology (e.g., Abcam®), or combinations thereof to determine the protein profile of the subject's biological sample.
[0134] Signature Panel The present disclosure provides methods and systems for analyzing biological samples to obtain measurable features from combinations of protein molecules identified in the samples associated with the development of colon cell proliferative disorders. The collection of identified protein molecules described herein has beneficial value in the creation of classifiers and models for the detection of colon cell proliferative disorders or stages thereof. While each identified protein molecule may be beneficial and useful, the protein molecules may be used in combination as described herein to form a signature panel whose signature is characteristic of a colon cell proliferative disorder or stage thereof. The signature panel features may be processed using a trained algorithm (e.g., a machine learning model) to create a classifier configured to stratify a population of subjects with colon cell proliferative disorders. The method is characterized by the use of one or more proteins described in the signature panel. In some embodiments, a signature panel of at least three proteins is useful for the classifiers and methods described herein.
[0135] The protein signature panels described herein allow for rapid and specific analysis of specific proteins associated with colon cell proliferative disorders. Signature panels as described and used in the methods herein may be used for improved diagnosis, prognosis, treatment selection, and monitoring (e.g., treatment monitoring) of colon cell proliferative disorders.
[0136] The signature panel and method provide a significant improvement over current approaches for detecting early stage colon cell proliferative disorders from body fluid samples such as whole blood, plasma, or serum. Current methods used to detect and diagnose colon cell proliferative disorders include colonoscopy, sigmoidoscopy, and fecal occult blood colon cancer. Compared to these methods, the method provided herein is much less invasive than colonoscopy and can be as sensitive, if not more sensitive, than sigmoidoscopy, immunological fecal occult blood test (FIT), and fecal occult blood test (FOBT). The method provided herein can provide significant advantages in terms of sensitivity and specificity due to the combination of the advantageous use of protein panels and highly sensitive assay technology.
[0137] The present disclosure provides a method and system directed to profiling proteins associated with colon cell proliferative disorders and disease progression. To identify proteins that are beneficial for the methods and classifiers described herein, plasma from patients with colon cell proliferative disorders and plasma from subjects without colon cell proliferative disorders (control or reference plasma) were examined to identify a signature panel of proteins produced by patients with colon cell proliferative disorders in response to colon cell proliferative disorders and their respective reactive proteins. To this end, plasma from patients with colon cell proliferative disorders and control plasma can be tested using high-density antibody microarrays. Antibody microarrays offer a series of advantages over other approaches used to identify proteins: i) the proteins printed on the array are known in advance, thereby preventing subsequent identification and eliminating possible selection of mimotopes; ii) there is no tendency to select any protein, since the proteins are all printed at similar concentrations; this combination of factors provides high sensitivity for identifying biomarkers.
[0138] The proteins identified herein can be used to identify subjects with colon cell proliferative disorders to distinguish them from subjects without colon cell proliferative disorders, or to identify subjects at high risk of developing colon cell proliferative disorders to distinguish them from subjects at low risk of developing colon cell proliferative disorders, or to identify subjects with precursor lesions of colon cell proliferative disorders. Thus, these proteins can be used as ancillary tools to guide decisions regarding monitoring, treatment, and management of colon cell proliferative disorders.
[0139] Disclosed herein, in some embodiments, are panels of plasma protein biomarkers useful for the early detection of proliferative disorders of the colon and for the early detection of colon cancer.
[0140] In other embodiments, methods relating to detection, diagnosis, and treatment are disclosed herein: Patient plasma is screened for tumor-associated or tumor-derived proteins as indicative of colonic proliferative disorders.
[0141] In one aspect, the present disclosure provides a method for the treatment of cancer, comprising administering to the patient a therapeutically effective amount of a therapeutically effective amount of a medicament for the treatment of cancer, the method comprising administering to the patient ... The present invention provides a protein panel characteristic of colon cell proliferative disorders comprising at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA.
[0142] In some embodiments, the panel is useful for indicating a sample from a subject having a colon cell proliferative disorder and comprises at least three proteins selected from the group consisting of complement component C2, complement component C9, factor D, factor I, complement component C1q, complement component C3, complement component C3b, factor B, and factor H.
[0143] In some embodiments, the protein panel includes FLT3L, CEACAM5, IL-6RA, CEA, ORM, or any combination thereof.
[0144] In some embodiments, the protein panel includes FLT3L, CEACAM5, IL-6RA, CEA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, or any combination thereof.
[0145] In some embodiments, the protein panel includes FLT3L, CEACAM5, IL-6RA, CEA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, AGRP, haptoglobin, ANGPTL4, FGF-23, complement component C2, ORM2, FGF-23, MUC-16, EGF, p00738, or any combination thereof.
[0146] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, or any combination thereof.
[0147] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, HGFR, THBS2, CA125 (MUC-16), CA19-9, CA15-3 (MUC-1), or any combination thereof.
[0148] In some embodiments, the panel comprises total PSA.
[0149] In some embodiments, the protein signature panels are useful for distinguishing between healthy subjects, subjects with benign colon polyps, subjects with advanced adenomas, or subjects with colon cancer.
[0150] In some embodiments, the panel is useful for indicating advanced adenomas and is indicative of EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo The antibody comprises at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA.
[0151] In some embodiments, the panel is useful for indicating samples from subjects with advanced adenomas and includes at least three proteins selected from the group consisting of complement component C2, complement component C9, factor D, factor I, complement component C1q, complement component C3, complement component C3b, factor B, and factor H.
[0152] In some embodiments, the panel is useful for indicative of colon cancer and includes EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo The antibody comprises at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA.
[0153] In some embodiments, the panel is useful for indicating samples from subjects with colon cancer and includes at least three proteins selected from the group consisting of complement component C2, complement component C9, factor D, factor I, complement component C1q, complement component C3, complement component C3b, factor B, and factor H.
[0154] In some embodiments, the predetermined set of proteins is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least At least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, or more proteins, such as those described herein. In some embodiments, the predetermined set of proteins contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 or more proteins, e.g., proteins described herein.In some embodiments, the predetermined set of proteins is selected from the group consisting of EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo In some embodiments, the predetermined set of proteins comprises a protein selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA. In some embodiments, the predetermined set of proteins comprises a protein selected from the group listed in Table 2.
[0155] In some embodiments, the proteins in the predetermined panel include proteins from functional classes such as interleukins, complement pathway mediators, complement proteins, chemokines, growth factors, cytokines, globulin proteins, mucins, and proteinases.
[0156] Classifiers, Machine Learning Models, and Systems Machine learning approaches are used to characterize protein data from subject biological samples to identify a panel of informative proteins. The identified panel of informative proteins for colon cell proliferative disorders is useful for training a classifier model that is useful for distinguishing healthy subject samples from subjects with colon cell proliferative disorders.
[0157] Further described herein is a machine learning model classifier trained on the proteins described herein expressed in plasma samples of healthy subjects and plasma samples of subjects with colon cell proliferative disorders. Training the machine learning model provides a classifier with a set of predefined protein biomarkers ("protein panel" or "signature panel") useful for classifying healthy subjects or subjects with colon cell proliferative disorders. In one example, a method is provided for a blood-based minimally invasive protein assay that can be used on subjects with colonic lesions to assess histological severity. In another embodiment, proteins indicative of colon cell proliferative disorders are detected in a subject's acellular sample, e.g., a subject's body fluid sample, such as whole blood, plasma, or serum. Thus, the proteins disclosed herein can be used to distinguish the presence or absence of colon cell proliferative disorders, high-risk or low-risk colonic lesions that require treatment, such as surgical resection, immunotherapy, radiation therapy, or chemotherapy, and to monitor low-risk colonic lesions. Monitoring and confirmation of the presence of colon cell proliferative disorders or lesions can be performed, for example, by colonoscopy, ultrasound, MM, or CT scan.
[0158] In some examples, the protein features are used as input data sets to trained algorithms (e.g., machine learning models or classifiers) to find correlations between protein profiles and groups of subjects (e.g., patient groups). Examples of such groups include the presence or absence of disease or disease, elevated or non-elevated risk of disease or disease, stage of disease or disease, subtype of disease or disease, responders to treatment vs. non-responders to treatment, and progressors vs. non-progressors. In some examples, feature matrices are generated to compare samples of subjects with known diseases or features. In some embodiments, the samples are from healthy subjects or subjects with no known indications and from patients known to have cancer.
[0159] As used herein, as it relates to machine learning and pattern recognition, the term "feature" generally refers to an individual measurable characteristic or feature of an observed phenomenon. The concept of a "feature" is related to the concept of an explanatory variable used in statistical methods such as, for example, but not limited to, linear regression and logistic regression. Features can be numerical or categorical (e.g., structural features such as strings and graphs are used in syntactic pattern recognition).
[0160] As used herein, the term "input feature" (or "feature") generally refers to a variable used by a trained algorithm (e.g., a machine learning model or classifier) to predict the output classification (label) of a sample, e.g., condition, protein identity, protein sequence content (e.g., mutation), proposed data collection operation, or proposed treatment. Values of the variables can be determined for a sample and used to determine the classification.
[0161] For multiple assays, the system identifies a feature set to input into a trained algorithm (e.g., a machine learning model or classifier). The system performs an assay on each biological sample and forms a feature vector from the measurements. The system inputs the feature vector into a machine learning model and obtains an output classification of whether the biological sample has a particular characteristic.
[0162] In some embodiments, the machine learning model outputs a classifier that can distinguish between two or more groups or classes of objects or features in a population of objects or features in a population. In some embodiments, the classifier is a trained machine learning classifier.
[0163] In some embodiments, informative loci or features of biomarkers in cancer tissues are assayed to form a profile. A receiver operating characteristic (ROC) curve can be generated by plotting the performance of a particular feature (e.g., any of the biomarkers and / or any of the items of additional biomedical information described herein) in distinguishing two populations (e.g., subjects who respond to a therapeutic agent and those who do not respond). In some embodiments, the feature data across the entire population (e.g., cases and controls) is sorted in ascending order based on the value of a single feature.
[0164] In various examples, the particular characteristic is selected from the group consisting of healthy versus cancer, elevated versus non-elevated risk of disease, disease subtype, disease stage, progressive versus non-progressive, and responder versus non-responder.
[0165] In some embodiments, the colon cell proliferative disorder is selected from the group consisting of adenoma (adenomatous polyp), polyposis disorder, Lynch syndrome, sessile serrated adenoma (SSA), advanced adenoma, colorectal dysplasia, colorectal adenoma, colorectal cancer, colon cancer, rectal cancer, colorectal carcinoma, colorectal adenocarcinoma, carcinoid tumor, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), lymphoma, and sarcoma.
[0166] A. Data Analysis In some examples, the disclosure provides a system, method, or kit with data analysis implemented in software applications, computing hardware, or both. In some examples, the analysis application or system includes at least a data receiving module, a data pre-processing module, a data analysis module (which can operate on one or more types of protein data), a data interpretation module, or a data visualization module. In some embodiments, the data receiving module includes a computer system that connects laboratory hardware or instrumentation to a computer system that processes laboratory data. In some embodiments, the data pre-processing module includes a hardware system or computer software that performs operations on the data in preparation for analysis. Examples of operations that may be applied to the data in the pre-processing module include affine transformations, noise removal operations, data cleaning, reformatting, or sub-sampling. The data analysis module may be specialized in analyzing genomic data from one or more genomic materials, for example, taking assembled genomic sequences and performing probabilistic and statistical analysis to identify abnormal patterns associated with a disease, pathology, state, risk, condition, or phenotype. The data interpretation module can use analytical methods derived from, for example, statistics, mathematics, or biology to support an understanding of the association between the identified abnormal patterns and health status, functional status, prognosis, or risk. The data visualization module can use methods of mathematical modeling, computer graphics, or rendering to create visual representations of the data that can facilitate understanding or interpretation of the results.
[0167] In some examples, machine learning methods are applied to distinguish between samples in a population of samples, hi some embodiments, machine learning methods are applied to distinguish between healthy samples and samples with progressive disease (e.g., adenomas).
[0168] In some embodiments, the one or more machine learning operations used to train the prediction engine include one or more of a generalized linear model, a generalized additive model, a non-parametric regression operation, a random forest classifier, a spatial regression operation, a Bayesian regression model, a time series analysis, a Bayesian network, a Gaussian network, a decision tree learning operation, an artificial neural network, a recurrent neural network, a reinforcement learning operation, a linear or non-linear regression operation, a support vector machine, a clustering operation, and a genetic algorithm operation.
[0169] In some examples, the computational method is selected from the group consisting of logistic regression, multiple linear regression (MLR), dimensionality reduction, partial least squares (PLS) regression, principal component regression, autoencoder, variational autoencoder, singular value decomposition, Fourier basis, wavelets, discriminant analysis, support vector machines, decision trees, classification and regression trees (CART), tree-based methods, random forests, gradient boosted trees, logistic regression, matrix decomposition, multidimensional scaling (MDS), dimensionality reduction methods, t-SNE, multilayer perceptron (MLP), network clustering, neuro-fuzzy, and artificial neural networks.
[0170] In some examples, the methods disclosed herein can include computational analysis of nucleic acid sequence data of a sample from a subject, or from multiple subjects.
[0171] B. Classifier generation In one aspect, the systems and methods disclosed herein provide a classifier that is generated based on feature information derived from protein analysis from a biological sample containing proteins. The classifier forms part of a prediction engine for distinguishing groups within a population based on features identified in the biological sample, such as proteins. The collective representation of the protein information in the biological sample may be referred to as a protein profile.
[0172] In some embodiments, the classifier is created by normalizing the protein information by formatting similar portions of the protein information into a uniform format and uniform scale, storing the normalized protein information in a columnar database, and training a prediction engine by applying one or more machine learning operations to the stored normalized protein information, where the prediction engine maps one or more feature combinations to define at least two classification groups for a particular population.
[0173] In some embodiments, the classifier is created by normalizing the protein information by formatting similar portions of the protein information into a uniform format and a uniform scale, storing the normalized protein information in a columnar database, and training a prediction engine by applying one or more machine learning operations to features of the stored normalized protein information to define at least two taxonomic groups.
[0174] In some embodiments, a prediction engine is applied to the population of objects from which normalized protein signatures are obtained and associated with each object in the population, and the output of the prediction engine is evaluated to identify objects associated with groups and classify the objects into taxa.
[0175] Specificity, as used herein, generally refers to the "probability of a negative test among people without the disease." Specificity can be calculated by dividing the number of disease-free individuals who test negative by the total number of disease-free subjects.
[0176] In some examples, the model, classifier, or predictive test has a specificity of at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99%.
[0177] Sensitivity, as used herein, generally refers to the "probability of a positive test among people with the disease." Sensitivity can be calculated by dividing the number of diseased individuals who test positive by the total number of diseased subjects.
[0178] In some examples, the model, classifier, or predictive test has a sensitivity of at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99%.
[0179] C. Digital Processing Devices In some examples, a digital processing device or its use is described herein. In some examples, the digital processing device may include one or more hardware central processing units (CPUs), graphic processing units (GPUs), or tensor processing units (TPUs) that perform the functions of the device. In some examples, the digital processing device may include an operating system configured to execute executable instructions.
[0180] In some examples, the digital processing device may optionally be connected to a computer network. In some examples, the digital processing device may optionally be connected to the Internet. In some examples, the digital processing device may optionally be connected to a cloud computing infrastructure. In some examples, the digital processing device may optionally be connected to an intranet. In some examples, the digital processing device may optionally be connected to a data storage device.
[0181] Non-limiting examples of suitable digital processing devices include server computers, desktop computers, laptop computers, notebook computers, subnotebook computers, netbook computers, netpad computers, set-top computers, handheld computers, Internet appliances, mobile smart phones, and tablet computers. Suitable tablet computers can include, for example, booklet, slate, and convertible configurations.
[0182] In some examples, the digital processing device may include an operating system configured to execute executable instructions. For example, an operating system may include software, including programs and data, that manages the hardware of the device and provides services for the execution of applications. Non-limiting examples of operating systems include Ubuntu, FreeBSD, OpenBSD, NetBSD®, Linux, Apple® Mac OS X Server®, Oracle® Solaris®, Windows Server®, and Novell® NetWare®. Non-limiting examples of suitable personal computer operating systems include Microsoft® Windows®, Apple® Mac OS X®, UNIX®, and UNIX-like operating systems, such as GNU / Linux®. In some examples, the operating system may be provided by cloud computing, and cloud computing resources may be provided by one or more service providers.
[0183] In some examples, the device may include a storage device and / or a memory device. The storage device and / or the memory device may be one or more physical devices used to temporarily or permanently store data or programs. In some examples, the device may be a volatile memory and may require power to maintain the stored information. In some examples, the device may be a non-volatile memory and may retain the stored information when power is not provided to the digital processing device. In some embodiments, the non-volatile memory may include a flash memory. In some examples, the non-volatile memory may include a dynamic random access memory (DRAM). In some examples, the non-volatile memory may include a ferroelectric random access memory (FRAM). In some examples, the non-volatile memory may include a phase change random access memory (PRAM).
[0184] In some examples, the device may be a storage device, including, for example, a CD-ROM, a DVD, a flash memory device, a magnetic disk drive, a magnetic tape drive, an optical disk drive, and a cloud computing-based storage. In some examples, the storage device and / or the memory device may be a combination of devices as disclosed herein. In some examples, the digital processing device may include a display for transmitting visual information to a user. In some examples, the display may be a cathode ray tube (CRT). In some examples, the display may be a liquid crystal display (LCD). In some examples, the display may be a thin film transistor liquid crystal display (TFT-LCD). In some examples, the display may be an organic light emitting diode (OLED) display. In some examples, the OLED display may be a passive matrix OLED (PMOLED) or an active matrix OLED (AMOLED) display. In some examples, the display may be a plasma display. In some examples, the display may be a video projector. In some examples, the display may be a combination of devices as disclosed herein.
[0185] In some examples, the digital processing device may include an input device for receiving information from a user. In some examples, the input device may be a keyboard. In some examples, the input device may be a pointing device including, for example, a mouse, a trackball, a trackpad, a joystick, a game controller, or a stylus. In some examples, the input device may be a touch screen or a multi-touch screen. In some examples, the input device may be a microphone that captures voice or other audio input. In some examples, the input device may be a video camera that captures motion or visual input. In some examples, the input device may be a combination of devices as disclosed herein.
[0186] D. Non-Transitory Computer-Readable Storage Medium In some examples, the subject matter disclosed herein may include one or more non-transitory computer-readable storage media encoded with a program including instructions executable by an operating system of an optionally networked digital processing device. In some examples, the computer-readable storage medium may be a tangible component of the digital processing device. In some examples, the computer-readable storage medium may be optionally removable from the digital processing device. In some examples, the computer-readable storage medium may include, for example, CD-ROMs, DVDs, flash memory devices, solid-state memories, magnetic disk drives, magnetic tape drives, optical disk drives, cloud computing systems, and services, etc. In some examples, the programs and instructions may be encoded on the medium permanently, nearly permanently, semi-permanently, or non-transitoryly.
[0187] E. Computer Systems The present disclosure provides a computer system programmed to implement the methods described herein. Figure 1 shows a computer system (101) programmed or otherwise configured to store, process, identify, or interpret patient data, biological data, biological sequences, reference sequences, and protein profiles. The computer system (101) can process various aspects of the patient data, biological data, biological sequences, reference sequences, and protein profiles of the present disclosure. The computer system (101) can be a user's electronic device or a computer system located remotely to the electronic device. The electronic device can be a mobile electronic device.
[0188] The computer system (101) includes a central processing unit (CPU, also referred to herein as "processor" and "computer processor") (105), which may be a single-core or multi-core processor, or multiple processors for parallel processing. The computer system (101) also includes memory or memory locations (110) (e.g., random access memory, read-only memory, flash memory), electronic storage (115) (e.g., hard disk), communication interfaces (120) (e.g., network adapters) for communicating with one or more other systems, and peripherals (125), such as cache, other memory, data storage devices, and / or electronic display adapters. The memory (110), storage (115), interface (120), and peripherals (125) communicate with the CPU (105) through a communication bus (solid lines), such as a motherboard. The storage (115) may be a data storage device (or data repository) for storing data. The computer system (101) may be operatively connected to a computer network ("network") (130) with the aid of the communication interface (120). The network (130) may be the Internet, an Internet and / or an extranet, or an intranet and / or an extranet in communication with the Internet. The network (130) may, in some examples, be a telecommunications and / or data network. The network (130) may include one or more computer servers, which may enable distributed computing, such as cloud computing. The network (130) may, in some examples, implement a peer-to-peer network with the aid of the computer system (101), thereby enabling devices coupled to the computer system (101) to act as clients or servers.
[0189] The CPU (105) can execute a series of machine-readable instructions, which may be embodied in a program or software. The instructions may be stored in a memory location, such as the memory (110). The instructions may be directed to the CPU (105), which can then program or otherwise configure the CPU (105) to implement the methods of the present disclosure. Examples of operations performed by the CPU (105) include fetch, decode, execute, and writeback.
[0190] The CPU 105 may be part of a circuit, such as an integrated circuit. One or more other components of the system 101 may be included in the circuit. In some examples, the circuit is an application specific integrated circuit (ASIC).
[0191] The storage device (115) can hold files such as drivers, libraries, and saved programs. The storage device (115) can hold user data, such as user personalization settings and user programs. The computer system (101) can include one or more additional data storage devices that are external to the computer system (101), such as located on a remote server in communication with the computer system (101) via an intranet or the Internet, in some examples.
[0192] The computer system (101) can communicate with one or more remote computer systems via the network (130). For example, the computer system (101) can communicate with a remote computer system of a user. Examples of remote computer systems include a personal computer (e.g., a portable PC), a slate or tablet PC (e.g., an Apple® iPad, a Samsung® Galaxy Tab), a phone, a smartphone (e.g., an Apple® iPhone, an Android-enabled device, a Blackberry®), or a personal digital assistant. A user can access the computer system (101) via the network (130).
[0193] Methods as described herein may be implemented by machine (e.g., computer processor) executable code stored in electronic memory locations of the computer system (101), such as, for example, on memory (110) or electronic storage (115). Machine executable or machine readable code may be provided in the form of software. In use, the code may be executed by the processor (105). In some examples, the code may be retrieved from storage (115) and stored on memory (110) for easy access by the processor (105). In some examples, electronic storage (115) may be omitted and machine executable instructions are stored in memory (110).
[0194] The code may be precompiled and configured for use on a machine having a suitable processor to execute the code, or may be interpreted or compiled during run-time. The code may be provided in a programming language, which may be selected to enable the code to be executed in a precompiled, interpreted, or as-compiled fashion.
[0195] Aspects of the systems and methods provided herein, such as the computer system (101), may be embodied in programming. Various aspects of the technology may be considered as "products" or "articles of manufacture" in the form of machine (or processor) executable code and / or associated data, typically carried on or embodied in a type of machine-readable medium. The machine executable code may be stored in electronic storage, such as memory (e.g., read-only memory, random access memory, flash memory) or a hard disk. A "storage" type medium may include any or all of the tangible memory of a computer or processor, or its associated modules, such as various semiconductor memories, tape drives, disk drives, etc., which may provide non-transitory recording media at any time for programming the software. All or portions of the software are sometimes communicated over the Internet or various other telecommunications networks. Such communication may enable, for example, loading of the software from one computer or processor to another, for example, from a management server or host computer to an application server computer platform. As such, other types of media for delivering software elements include light waves, radio waves, and electromagnetic waves, such as those used across physical interfaces between local devices, via wired and optical terrestrial communications networks and various air links. Physical elements that carry such waves, such as wired or wireless links, optical links, etc., may also be considered media for delivering software. As used herein, unless limited to non-transitory, tangible "storage" media, terms such as computer or machine "readable medium" generally refer to media that participate in providing instructions to a processor for execution.
[0196] Thus, a machine-readable medium such as a computer executable code may take many forms, including but not limited to a tangible storage medium, a carrier wave medium, or a physical transmission medium. Non-volatile storage media include, for example, optical or magnetic disks, such as any of the storage devices in any computer, such as may be used to implement the databases described herein. Volatile storage media include dynamic memory, such as the main memory of a computer platform described herein. Tangible transmission media include copper wire and fiber optics, including coaxial cables, wires that comprise a bus in a computer system. Carrier wave transmission media may take the form of electric or electromagnetic signals, or sound or light waves, such as those generated during radio frequency (RF) and infrared (IR) data communications. Thus, common forms of computer readable media include, for example, floppy disks, flexible disks, hard disks, magnetic tape, other magnetic media, CD-ROMs, DVDs or DVD-ROMs, other optical media, punch cards, paper tape, other physical storage media with patterns of holes, RAM, ROM, PROMs and EPROMs, FLASH-EPROMs, other memory chips or cartridges, carrier waves carrying data or instructions, cables or links which transmit such carrier waves, or other media from which a computer may read programming code and / or data. Many of these forms of computer readable media may be involved in carrying one or more sequences of one or more instructions to a processor for execution.
[0197] The computer system (101) can include or communicate with an electronic display (135) that includes a user interface (UI) (140) for providing, for example, analysis of nucleic acid sequences, enriched nucleic acid sample data, protein profiles, expression profiles, and RNA expression profiles. Examples of UIs include, but are not limited to, graphical user interfaces (GUIs) and web-based user interfaces.
[0198] The methods and systems of the present disclosure may be implemented by one or more algorithms. The algorithms may be implemented by software after execution by the central processing unit (105). The algorithms may, for example, store, process, identify, or interpret patient data, biological data, biological sequences, reference sequences, and protein profiles.
[0199] In some examples, the subject matter disclosed herein may include at least one computer program or its use. A computer program may be a set of instructions written to perform a specified task and executable in a CPU, GPU, or TPU of a digital processing device. Computer-readable instructions may be implemented as program modules, such as functions, objects, application programming interfaces (APIs), data structures, etc., that perform a specific task or implement a specific abstract data type. In light of the disclosure provided herein, computer programs may be written in a variety of languages and in a variety of versions.
[0200] The functionality of the computer readable instructions may be combined or distributed as desired in various environments. In some examples, a computer program may include one sequence of instructions. In some examples, a computer program may include multiple sequences of instructions. In some examples, a computer program may be provided from one location. In some examples, a computer program may be provided from multiple locations. In some examples, a computer program may include one or more software modules. In some examples, a computer program may include, in part or in whole, one or more web applications, one or more mobile applications, one or more standalone applications, one or more web browser plug-ins, extensions, add-ins, or add-ons, or combinations thereof.
[0201] In some examples, the computational processing may be a method of statistics, mathematics, biology, or any combination thereof. In some examples, the computational processing method includes a dimension reduction method including, for example, logistic regression, dimensionality reduction, principal component analysis, autoencoder, singular value decomposition, Fourier basis, singular value decomposition, wavelet, discriminant analysis, support vector machine, tree-based methods, random forests, gradient boosted trees, logistic regression, matrix decomposition, network clustering, and neural networks.
[0202] In some examples, the computational methods are supervised machine learning methods including, for example, regression, support vector machines, tree-based methods, and networks.
[0203] In some examples, the computational methods are unsupervised machine learning methods including, for example, clustering, networks, principal component analysis, and matrix decomposition.
[0204] F. Database In some examples, the subject matter disclosed herein can include one or more databases for storing patient data, biological data, biological sequences, reference sequences, or protein profiles, or the use thereof. Reference sequences can be extracted from databases. In view of the disclosure provided herein, many databases can be suitable for storing and searching sequence information. In some examples, suitable databases can include, for example, relational databases, non-relational databases, object-oriented databases, object databases, entity-relationship model databases, associative databases, and XML databases. In some examples, the database can be internet-based. In some examples, the database can be web-based. In some examples, the database can be cloud computing-based. In some examples, the database can be based on one or more local computer storage devices.
[0205] In one aspect, the present disclosure provides a non-transitory computer-readable medium comprising instructions directing a processor to perform the methods disclosed herein.
[0206] In one aspect, the present disclosure provides a computing device that includes a computer-readable medium.
[0207] In another aspect, the present disclosure provides a system for performing classification of a biological sample, comprising: a) a receiver receiving a plurality of training samples, each of the plurality of training samples having a plurality of molecular classes, each of the plurality of training samples including one or more known labels; b) a feature module that identifies a set of features corresponding to an assay that is operable to be computed using a machine learning model for each of a plurality of training samples, where for each of the plurality of training samples, the set of features corresponds to a characteristic of molecules in the plurality of training samples, and where the system is operable to subject a plurality of classes of molecules in the training samples to a plurality of different assays to obtain a set of measurements, where each set of measurements is from one assay applied to a class of molecules in the training sample, and where the set of measurements is obtained for the plurality of training samples; c) an analysis module for analyzing the set of measurements to obtain a training vector for the training sample, the training vector including feature values for the N sets of features of the corresponding assay, each feature value corresponding to a feature and including one or more measurements, the training vector being formed using at least one feature from at least two of the N sets of features corresponding to a first subset of the plurality of different assays; d) a labeling module that uses parameters of the machine learning model to inform the system about the training vectors to obtain output labels for a number of training samples; e) a comparison module that compares the output labels with known labels of training samples; f) a training module that iteratively searches for optimal values for parameters as part of training the machine learning model based on a comparison of the output labels with known labels of the training samples; g) an output module that provides machine learning model parameters and a set of machine learning model features; The present invention provides a system including:
[0208] A method for classifying objects in a population The disclosed method is directed to identifying protein expression parameters associated with colon cell proliferative disorders through the analysis of proteins expressed in a subject. The method is for use in improved diagnosis, treatment and monitoring of colon cell proliferative disorders, more specifically by allowing identification of stages or subclasses of said disorders and genetic predispositions to said disorders, and improved identification thereof.
[0209] In some embodiments, the methods comprise analyzing differential expression of proteins in biological samples of subjects in a population.
[0210] The present disclosure provides methods for detecting colon cell proliferative disorders that can be applied to acellular samples, such as methods for detecting the presence and characteristics of proteins between subjects with and without a colon cell proliferative disorder, or between different colon cell proliferative disorders, which utilize the detection of proteins as basic "positive" or "negative" signals of a colon cell proliferative disorder compared to healthy subjects without the colon cell proliferative disorder.
[0211] In some embodiments, the colon cell proliferative disorder is selected from the group consisting of adenoma (adenomatous polyp), polyposis disorder, Lynch syndrome, sessile serrated adenoma (SSA), advanced adenoma, colorectal dysplasia, colorectal adenoma, colorectal cancer, colon cancer, rectal cancer, colorectal carcinoma, colorectal adenocarcinoma, carcinoid tumor, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), lymphoma, and sarcoma.
[0212] In one aspect, the present disclosure provides a method for determining a protein profile of a biological sample containing a protein of interest, comprising: a) obtaining a protein-containing biological sample from a subject; b) EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo measuring the presence and amount of a predetermined panel of at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, providing a protein profile of the subject; The present invention provides a method comprising:
[0213] In some embodiments, the protein profile is associated with a colon cell proliferative disorder and provides a classification of subjects with a colon cell proliferative disorder.
[0214] In some embodiments, the subject's biological sample is selected from the group consisting of bodily fluids, stool, colonic discharge, urine, plasma, serum, whole blood, isolated blood cells, cells isolated from blood, and combinations thereof.
[0215] In some embodiments, the colon cell proliferative disorder is selected from the group consisting of adenoma (adenomatous polyp), polyposis disorder, Lynch syndrome, sessile serrated adenoma (SSA), advanced adenoma, colorectal dysplasia, colorectal adenoma, colorectal cancer, colon cancer, rectal cancer, colorectal carcinoma, colorectal adenocarcinoma, carcinoid tumor, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), lymphoma, and sarcoma.
[0216] In some embodiments, the colon cell proliferative disorder is selected from the group consisting of stage 1 colon cancer, stage 2 colon cancer, stage 3 colon cancer, and stage 4 colon cancer.
[0217] In some embodiments, the advanced adenoma is a tubular adenoma, tubulovillous adenoma, villous adenoma, adenocarcinoma, or hyperplastic polyp.
[0218] In another aspect, the disclosure provides a method of detecting a colon cell proliferative disorder in a subject, comprising: a) obtaining a protein-containing biological sample from a subject; b) EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo measuring the presence and amount of a predetermined panel of at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, providing a protein profile of the subject; c) computing the protein profile into a machine learning model trained to distinguish between healthy subjects and subjects with a colon cell proliferative disorder to provide an output value related to the presence or absence of a colon cell proliferative disorder, thereby indicating the presence or absence of a colon cell proliferative disorder in the subject; The present invention provides a method comprising:
[0219] In some embodiments, the subject's biological sample is selected from the group consisting of bodily fluids, stool, colonic discharge, urine, plasma, serum, whole blood, isolated blood cells, cells isolated from blood, and combinations thereof.
[0220] In another aspect, disclosed herein is a method for detecting proteins to generate a protein profile in a sample, the method comprising: a) obtaining a protein-containing biological sample from a subject; b) EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo measuring the presence and amount of a predetermined panel of at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, providing a protein profile of the biological sample; Includes.
[0221] In another aspect, disclosed herein is a method of obtaining data in a biological sample of a subject, comprising detecting at least six proteins, and optionally determining the levels of said at least six proteins in the sample, said at least six proteins being selected from the group consisting of EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA.
[0222] In some embodiments, the colon cell proliferative disorder is selected from the group consisting of adenoma (adenomatous polyp), polyposis disorder, Lynch syndrome, sessile serrated adenoma (SSA), advanced adenoma, colorectal dysplasia, colorectal adenoma, colorectal cancer, colon cancer, rectal cancer, colorectal carcinoma, colorectal adenocarcinoma, carcinoid tumor, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), lymphoma, and sarcoma.
[0223] In some embodiments, the colon cell proliferative disorder is selected from the group consisting of stage 1 colon cancer, stage 2 colon cancer, stage 3 colon cancer, and stage 4 colon cancer.
[0224] In another aspect, the present disclosure provides a method for providing a protein profile of a subject, comprising: a) obtaining a protein-containing biological sample from a subject; b) EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo measuring the presence and amount of a predetermined panel of at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, thereby determining the subject's protein profile; The present invention provides a method for determining a protein profile of a biological sample containing proteins from a subject comprising:
[0225] In some embodiments, the predetermined panel of proteins comprises FLT3L, CEACAM5, IL-6RA, ORM, or any combination thereof.
[0226] In some embodiments, the predetermined panel of proteins includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, or any combination thereof.
[0227] In some embodiments, the predetermined panel of proteins includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, AGRP, haptoglobin, ANGPTL4, FGF-23, complement component C2, ORM2, FGF-23, MUC-16, EGF, or any combination thereof.
[0228] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, or a combination thereof.
[0229] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, HGFR, THBS2, CA125 (MUC-16), CA19-9, CA15-3 (MUC-1), or a combination thereof.
[0230] In some embodiments, the panel comprises total PSA.
[0231] In another aspect, the disclosure provides a method of detecting a colon cell proliferative disorder in a subject, comprising: a) obtaining a protein-containing biological sample from a subject; b) EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo measuring the presence and amount of a predetermined panel of at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, providing a protein profile of the subject; c) computing the subject's protein profile into a machine learning model trained to distinguish between subjects without a colon cell proliferative disorder and subjects with a colon cell proliferative disorder; d) outputting a value associated with the subject having a colon cell proliferative disorder based on the protein profile by the machine learning model, thereby detecting a colon cell proliferative disorder in the subject; The present invention provides a method for detecting a colon cell proliferative disorder in a subject comprising:
[0232] In another aspect, the disclosure provides a method for monitoring minimal residual disease in a subject previously treated for a disease, comprising: detecting a signal from a subject with a signal transduction pathway that includes ... determining a protein profile of the subject's biological sample using a predetermined panel of proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, Factor B, Factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, thereby generating a baseline protein status; and determining a protein profile of the subject's biological sample at one or more time points after generation of the baseline protein status, thereby generating a current protein status, wherein a change between the baseline protein status and the current protein status indicates a change in minimal residual disease in the subject.
[0233] In some embodiments, minimal residual disease is selected from the group consisting of response to treatment, tumor burden, post-operative residual tumor, recurrence, secondary screen, primary screen, and cancer progression.
[0234] The trained machine learning methods, models, and discriminatory classifiers described herein can be applied to a variety of medical applications, including cancer detection, diagnosis, and treatment response. Because models can be trained with subject metadata and analyte-derived features, applications can be tailored to stratify subjects within a population and guide treatment decisions accordingly.
[0235] diagnosis The methods and systems provided herein may perform predictive analytics using an artificial intelligence based approach to analyze data acquired from a subject (patient) to generate an output of a diagnosis for a subject having cancer (e.g., colon cancer). For example, an application may apply a predictive algorithm to the acquired data to generate a diagnosis for a subject having cancer. The predictive algorithm may include an artificial intelligence based predictor, such as a machine learning based predictor, configured to process the acquired data to generate a diagnosis for a subject having cancer.
[0236] The machine learning predictor can be trained using a dataset, e.g., a dataset generated by performing protein assays on subject biological samples from one or more sets of cohorts of patients with cancer using a signature panel described herein, as input to the machine learning predictor, and the subject's known diagnostic (e.g., staging and / or tumor fraction) outcomes as output.
[0237] A training dataset (e.g., a dataset generated by performing an assay using the signature panel described herein on a subject's biological sample) may be generated, for example, from one or more sets of subjects with common characteristics (features) and results (labels). A training dataset may include a set of features and labels corresponding to diagnostic features. Features may include features such as, for example, a particular range or category of protein assay measurements, such as the presence or characteristics of one or more proteins in biological samples of healthy and diseased subjects. For example, a set of features collected from a given subject at a given time point may collectively serve as a diagnostic signature that may indicate the subject's identified cancer at a given time point. Also, features may include a label that indicates the subject's diagnostic outcome, for example, for one or more cancers.
[0238] The label may include a result, such as, for example, a known diagnostic (e.g., staging and / or tumor fraction) result for the subject. The result may include a characteristic associated with a cancer in the subject. For example, the characteristic may indicate the subject has one or more cancers.
[0239] The training set (e.g., training data set) may be selected by random sampling of a set of data corresponding to one or more sets of subjects (e.g., retrospective and / or prospective cohorts of patients with or without one or more cancers). Alternatively, the training set (e.g., training data set) may be selected by proportional sampling of a set of data corresponding to one or more sets of subjects (e.g., retrospective and / or prospective cohorts of patients with or without one or more cancers). The training set may be balanced across sets of data corresponding to one or more sets of subjects (e.g., patients from various clinical sites or clinical trials). The machine learning predictor may be trained until certain predetermined conditions regarding accuracy or performance are met, such as having a minimum desired value corresponding to a measure of diagnostic accuracy. For example, the measure of diagnostic accuracy may correspond to the prediction of the diagnosis, staging, or tumor fraction of one or more cancers in the subject.
[0240] Examples of measures of diagnostic accuracy may include sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and the area under the curve (AUC) of the receiver operating characteristic (ROC) curve, which corresponds to the diagnostic accuracy of detecting or predicting cancer (e.g., colon cancer).
[0241] In one aspect, the present disclosure provides a method of using a classifier capable of distinguishing populations of subjects, comprising: a) obtaining a protein-containing biological sample from a subject; b) EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo measuring the presence and amount of a predetermined panel of at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, thereby providing a protein profile of the subject; c) computing the subject protein profile into a machine learning model trained to distinguish among two or more populations; d) outputting a value associated with the population by the machine learning model based on the protein profile, thereby distinguishing the population of interest; The present invention provides a method comprising:
[0242] In some embodiments, the predetermined panel of proteins comprises FLT3L, CEACAM5, IL-6RA, ORM, or any combination thereof.
[0243] In some embodiments, the predetermined panel of proteins includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, or any combination thereof.
[0244] In some embodiments, the predetermined panel of proteins includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, AGRP, haptoglobin, ANGPTL4, FGF-23, complement component C2, ORM2, FGF-23, MUC-16, EGF, or any combination thereof.
[0245] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, or a combination thereof.
[0246] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, HGFR, THBS2, CA125 (MUC-16), CA19-9, CA15-3 (MUC-1), or a combination thereof.
[0247] In some embodiments, the panel comprises total PSA.
[0248] In another aspect, the disclosure provides a method of identifying cancer in a subject, comprising: a) obtaining a protein-containing biological sample from a subject; b) EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein 6, mesothelin, EpCAM, Apo measuring the presence and amount of a predetermined panel of at least six proteins selected from the group consisting of A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, thereby providing a protein profile of the subject; c) computing the protein profile into a machine learning model trained to distinguish between healthy subjects and subjects with a colon cell proliferative disorder to provide an output value related to the presence or absence of a colon cell proliferative disorder, thereby indicating the presence or absence of a colon cell proliferative disorder in a subject and generating a probability that said subject has said cancer; The present invention provides a method comprising:
[0249] In some embodiments, the predetermined panel of proteins comprises FLT3L, CEACAM5, IL-6RA, ORM, or any combination thereof.
[0250] In some embodiments, the predetermined panel of proteins includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, or any combination thereof.
[0251] In some embodiments, the predetermined panel of proteins includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, GDF-15, AGRP, haptoglobin, ANGPTL4, FGF-23, complement component C2, ORM2, FGF-23, MUC-16, EGF, or any combination thereof.
[0252] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, or a combination thereof.
[0253] In some embodiments, the panel includes FLT3L, CEACAM5, IL-6, IL-8, MIP-3a, IL-1RT2, TNC, HGFR, THBS2, CA125 (MUC-16), CA19-9, CA15-3 (MUC-1), or a combination thereof.
[0254] In some embodiments, the panel comprises total PSA.
[0255] Various statistical and mathematical methods for establishing expression threshold or cut-off levels can be used. Threshold or cut-off expression levels for a particular biomarker can be selected based on data from a receiver operating characteristic (ROC) plot, for example, as described in the examples and figures disclosed herein. Those skilled in the art will understand that these threshold or cut-off expression levels can be changed, for example, by moving along the ROC plot for a particular biomarker or combinations thereof, to obtain different values for sensitivity or specificity, thereby affecting the overall assay performance. For example, if the objective is to have a robust diagnostic method from a clinical perspective, high sensitivity should be prioritized. However, if the objective is to have a cost-effective method, high specificity should be prioritized. The best cut-off refers to the value obtained from the ROC plot for a particular biomarker that produces the best sensitivity and specificity. Sensitivity and specificity values are calculated over a range of thresholds (cut-offs). Thus, the threshold or cutoff value can be selected to have a sensitivity and / or specificity of at least about 50% in at least 60%, at least 65%, at least 70%, at least 75%, or at least 80% of the patient population assayed, and can be, for example, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100%.
[0256] Thus, some embodiments of the present disclosure are carried out by determining the presence and / or level of at least the above cited proteins in an isolated minimally invasive sample of a subject to be diagnosed or screened, and comparing the presence and / or level of the proteins to a predetermined threshold or cut-off value, which corresponds to the expression level of said proteins that correlates with the highest specificity at a desired sensitivity in an ROC curve calculated based on the expression levels of the proteins determined in a patient population at risk of suffering from colorectal cancer or colorectal adenoma, and overexpression of at least one of said proteins relative to said predetermined cut-off value is indicative of a subject suffering from colorectal cancer or colorectal adenoma with said desired sensitivity.
[0257] As another example, such a predetermined condition may be that the specificity for predicting a colon cell proliferative disorder includes values, e.g., at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.
[0258] As another example, such a predetermined condition may be that the positive predictive value (PPV) for predicting a colon cell proliferative disorder includes values, e.g., at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.
[0259] As another example, such a predetermined condition may be that the negative predictive value (NPV) for predicting a colon cell proliferative disorder includes values, e.g., at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.
[0260] As another example, such a predetermined condition may be that the area under the curve (AUC) of a receiver operating characteristic (ROC) predicting colon cell proliferative disorder comprises a value of at least about 0.50, at least about 0.55, at least about 0.60, at least about 0.65, at least about 0.70, at least about 0.75, at least about 0.80, at least about 0.85, at least about 0.90, at least about 0.95, at least about 0.96, at least about 0.97, at least about 0.98, or at least about 0.99.
[0261] Colon Cancer Monitoring After using the trained algorithm to process the data set, colon cancer may be identified or monitored in the subject.Identification may be based at least in part on the quantitative measurement of the protein of the data set of the panel of colon cancer-related proteins.For example, monitoring may include evaluating the colon cancer of the subject at each or two or more different time points.
[0262] In some embodiments, the methods disclosed herein may be applied to monitoring and / or predicting tumor burden.
[0263] In some embodiments, the methods disclosed herein may be applied to detecting and / or predicting post-operative residual tumor.
[0264] In some embodiments, the methods disclosed herein may be applied to detecting and / or predicting minimal residual disease after surgery.
[0265] In some embodiments, the methods disclosed herein may be applied to detecting and / or predicting recurrence.
[0266] In one aspect, the methods disclosed herein may be applied as a secondary screen.
[0267] In one aspect, the methods disclosed herein may be applied as a primary screen.
[0268] In one aspect, the methods disclosed herein may be applied to monitoring the development of cancer.
[0269] In one embodiment, the methods disclosed herein may be applied to monitoring and / or predicting cancer risk.
[0270] Colon cancer may be identified in a subject with an accuracy of at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more. The accuracy of identifying colon cancer by a trained algorithm may be calculated as the percentage of independent test samples (e.g., subjects known to have colon cancer or subjects with negative clinical results for colon cancer) that are correctly identified or classified as having or not having colon cancer.
[0271] Colon cancer may be identified in a subject with a positive predictive value (PPV) of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or more. The PPV of identifying colon cancer using the trained algorithm may be calculated as the proportion of cell-free biological samples identified or classified as having colon cancer that represent subjects who truly have colon cancer.
[0272] Colon cancer may be identified in a subject with a negative predictive value (NPV) of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or more. The NPV of identifying colorectal cancer using the trained algorithm can be calculated as the proportion of cell-free biological samples identified or classified as not having colorectal cancer that represent subjects who truly do not have colorectal cancer.
[0273] Colorectal cancer is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, , at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, at least about 99.9%, at least about 99.99%, at least about 99.999%, or more. The clinical sensitivity of identifying colorectal cancer using a trained algorithm can be calculated as the proportion of independent test samples associated with the presence of colorectal cancer (e.g., subjects known to have colorectal cancer) that are correctly identified or classified as having colorectal cancer.
[0274] Colorectal cancer is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, , at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, at least about 99.9%, at least about 99.99%, at least about 99.999%, or more. The clinical specificity of identifying colorectal cancer using a trained algorithm can be calculated as the proportion of independent test samples associated with the absence of colorectal cancer (e.g., subjects with negative clinical test results for colorectal cancer) that are correctly identified or classified as not having colorectal cancer.
[0275] In some embodiments, the trained algorithm may determine that the subject has at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or more risk of colorectal cancer.
[0276] The trained algorithm may be at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about The subject may be determined to be at risk of colorectal cancer with an accuracy of 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, at least about 99.9%, at least about 99.99%, at least about 99.999% or greater.
[0277] Once a subject is identified as having colon cancer, the subject can optionally be provided with a therapeutic intervention (e.g., prescribing an appropriate treatment course for treating the subject's colon cancer).Therapeutic intervention can include prescribing an effective dose of a drug, further testing or evaluation of colon cancer, further monitoring of colon cancer, or a combination thereof.If the subject is currently undergoing treatment for colon cancer in a treatment course, therapeutic intervention can include a subsequent different treatment course (e.g., increasing treatment effectiveness due to the ineffectiveness of the current treatment course).
[0278] Therapeutic intervention may include recommending a second clinical trial to confirm the diagnosis of colorectal cancer, which may include imaging tests, blood tests, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, ultrasound scans, chest x-rays, positron emission tomography (PET) scans, PET-CT scans, acellular biological cytology, FIT tests, FOBT tests, or any combination thereof.
[0279] The colon cancer of the subject can be monitored by monitoring the treatment process for treating the colon cancer of the subject.Monitoring can include evaluating the colon cancer of the subject at two or more time points.Evaluation can be based on at least the quantitative measure of the protein of the panel of colon cancer-associated proteins data set, comprising the quantitative measure of the panel of colon cancer-associated proteins determined at each of two or more time points.
[0280] In some embodiments, differences in the quantitative measures of proteins of a dataset of a panel of colon cancer associated proteins comprising quantitative measures of a panel of colon cancer associated proteins determined between two or more time points may be indicative of one or more clinical indications, such as (i) a diagnosis of colon cancer in the subject, (ii) a prognosis of colon cancer in the subject, (iii) an increased risk of colon cancer in the subject, (iv) a decreased risk of colon cancer in the subject, (v) the effectiveness of a course of treatment for treating colon cancer in the subject, and (vi) the ineffectiveness of a course of treatment for treating colon cancer in the subject.
[0281] In some embodiments, the difference in the quantitative measure of protein, including the quantitative measure of the panel of colon cancer-associated proteins, determined between two or more time points can indicate a diagnosis of colon cancer in the subject. For example, if colon cancer is not detected in the subject at an earlier time point, but is detected in the subject at a later time point, the difference indicates a diagnosis of colon cancer in the subject. Based on this indication of the diagnosis of colon cancer in the subject, a clinical action or clinical decision can be made, such as, for example, prescribing a new therapeutic intervention for the subject. The clinical action or clinical decision can include recommending a second clinical trial to the subject to confirm the diagnosis of colon cancer. This second clinical trial can include imaging tests, blood tests, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, ultrasound scans, chest X-rays, positron emission tomography (PET) scans, PET-CT scans, acellular biological cytology, FIT tests, FOBT tests, or any combination thereof.
[0282] In some embodiments, a difference in the quantitative measure of proteins in a dataset of a panel of colon cancer associated proteins comprising the quantitative measure of a panel of colon cancer associated proteins determined between two or more time points may be indicative of a prognosis of colon cancer in a subject.
[0283] In some embodiments, a difference in the quantitative measure of a protein of a dataset in a panel of colon cancer-associated proteins, comprising the quantitative measure of a panel of colon cancer-associated proteins determined between two or more time points, may indicate a subject with an increased risk of colon cancer. For example, if colon cancer is detected in a subject at both an earlier time point and a later time point, and if the difference is a positive difference (e.g., the quantitative measure of a protein of a dataset in a panel of colon cancer-associated proteins increases from an earlier time point to a later time point), the difference may indicate that the subject has an increased risk of colon cancer. Based on this indication of increased risk of colon cancer, a clinical action or decision may be made, such as, for example, prescribing a new therapeutic intervention for the subject or switching a therapeutic intervention (e.g., terminating a current treatment and prescribing a new treatment). A clinical action or decision may include recommending a second clinical trial to the subject to confirm the increased risk of colon cancer. This second-stage clinical trial may include imaging tests, blood tests, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, ultrasound scans, chest x-rays, positron emission tomography (PET) scans, PET-CT scans, acellular biological cytology, FIT tests, FOBT tests, or any combination thereof.
[0284] In some embodiments, the difference in the quantitative measure of the protein of the panel of colon cancer-associated proteins of the dataset comprising the quantitative measure of the panel of colon cancer-associated proteins determined between two or more time points can indicate the subject has a reduced risk of colon cancer.For example, if colon cancer is detected in the subject at both the earlier and later time points, and if the difference is a negative difference (e.g., the quantitative measure of the protein of the dataset of the panel of colon cancer-associated proteins comprising the quantitative measure of the panel of colon cancer-associated proteins decreases from the earlier time point to the later time point), the difference can indicate that the subject has a reduced risk of colon cancer.A clinical action or decision can be made for the subject based on this indication of reduced risk of colon cancer (e.g., continue or terminate current therapeutic intervention).A clinical action or decision can include recommending the subject for a secondary clinical trial to confirm the reduced risk of colon cancer. This second-stage clinical trial may include imaging tests, blood tests, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, ultrasound scans, chest x-rays, positron emission tomography (PET) scans, PET-CT scans, acellular biological cytology, FIT tests, FOBT tests, or any combination thereof.
[0285] In some embodiments, the difference in the quantitative measure of the protein of the dataset in the panel of colon cancer-associated proteins, including the quantitative measure of the panel of colon cancer-associated proteins determined between two or more time points, can indicate the effectiveness of the treatment course for treating the subject's colon cancer. For example, if colon cancer is detected in the subject at an earlier time point, but not at a later time point, the difference can indicate the effectiveness of the treatment course for treating the subject's colon cancer. Based on this indication of the effectiveness of the treatment course for treating the subject's colon cancer, a clinical action or clinical decision can be made, such as, for example, to continue or terminate the current therapeutic intervention. The clinical action or clinical decision can include recommending the subject for a secondary clinical trial to confirm the effectiveness of the treatment course for treating colon cancer. This secondary clinical trial can include imaging tests, blood tests, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, ultrasound scans, chest x-rays, positron emission tomography (PET) scans, PET-CT scans, acellular biological cytology, FIT tests, FOBT tests, or any combination thereof.
[0286] In some embodiments, the difference in the quantitative measure of the protein of the dataset in the panel of colon cancer-associated proteins, which comprises the quantitative measure of the panel of colon cancer-associated proteins, determined between two or more time points, may indicate the ineffectiveness of the treatment course for treating the subject's colon cancer. For example, if colon cancer is detected in the subject at both the earlier and later time points, and if the difference is a positive or zero difference (e.g., the quantitative measure of the protein of the dataset in the panel of colon cancer-associated proteins, which comprises the quantitative measure of the panel of colon cancer-associated proteins, increased or remained at a constant level from the earlier time point to the later time point), and if effective treatment is indicated at the earlier time point, the difference may indicate the ineffectiveness of the treatment course for treating the subject's colon cancer. Based on this indication of the ineffectiveness of the treatment course for treating the subject's colon cancer, a clinical action or clinical decision may be made, such as, for example, terminating the current therapeutic intervention for the subject and / or switching (e.g., prescribing) a different new therapeutic intervention. The clinical action or clinical decision may include recommending the subject to a secondary clinical trial to confirm the ineffectiveness of the treatment course for treating colon cancer. This second-stage clinical trial may include imaging tests, blood tests, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, ultrasound scans, chest x-rays, positron emission tomography (PET) scans, PET-CT scans, acellular biological cytology, FIT tests, FOBT tests, or any combination thereof.
[0287] kit The present disclosure provides a kit for identifying or monitoring cancer in a subject. The kit may include an antibody, probe, or primer for identifying a quantitative measure (e.g., indicating the presence, absence, or relative amount) of a protein in each of a plurality of cancer-associated proteins in a cell-free biological sample of a subject. The quantitative measure (e.g., indicating the presence, absence, or relative amount) of a panel of proteins in a cell-free biological sample may indicate one or more cancers. The probe may be selective for a protein in a cell-free biological sample. The kit may include instructions for using the probe to process a cell-free biological sample to generate a data set that indicates a quantitative measure (e.g., indicating the presence, absence, or relative amount) of a protein in a cell-free biological sample of a subject.
[0288] The probes in the kit may be selective for a protein or a sequence encoding a protein in a plurality of cancer-associated proteins in a cell-free biological sample. The probes in the kit may be configured to selectively enrich protein molecules corresponding to a plurality of cancer-associated proteins. The probes in the kit may be antibodies that are recognized by the protein and tagged to allow isolation after binding to the protein in the biological sample.
[0289] The instructions in the kit may include instructions to assay the acellular biological sample with a probe selective for a cancer associated protein in the acellular biological sample. A quantitative measure (e.g., indicating the presence, absence, or relative amount) of a protein or protein-encoding sequence in each of a plurality of cancer associated proteins in the acellular biological sample may be indicative of one or more cancers.
[0290] The instructions in the kit may include instructions for measuring and interpreting an assay readout, which may be quantified in one or more of the multiple cancer-associated proteins to generate a data set indicative of a quantitative measure (e.g., indicating the presence, absence, or relative amount) of the protein or protein-encoding sequence in each of the multiple cancer-associated proteins in the cell-free biological sample. EXAMPLES
[0291] Example 1: Protein analysis in patient plasma samples
[0292] In cancer, proteins, whether they are cancer neoantigens or canonical proteins, are a source of potential early diagnostic biomarkers for colon cancer. Protein characteristics can be determined from plasma by evaluating protein overexpression, depletion, or mutation in cancer patients. Several proteins have been identified to be associated with breast, prostate, colon, lung, and ovarian cancer.
[0293] To identify proteins that are useful for the methods and classifiers described herein, plasma from patients with colon cell proliferative disorder and plasma from subjects without colon cell proliferative disorder (control plasma or reference plasma) were examined to identify a signature panel of proteins produced by patients with colon cell proliferative disorder in response to colon cell proliferative disorder and their respective reactive proteins.To this end, plasma from patients with colon cell proliferative disorder and control plasma were profiled using both mass spectrometry-based proteomics and immunoaffinity assays to identify and quantify circulating plasma proteins.Plasma may or may not be depleted of high abundance proteins (e.g., albumin, immunoglobulins) prior to characterization.
[0294] The protein panel identified by this analysis allowed differentiation between the plasma of subjects with colon cell proliferative disorders and healthy subjects.
[0295] method Sample classification To detect proteins in plasma samples, immunoassays and mass spectrometry assays were performed using plasma collected from subjects who were subsequently identified as having colorectal cancer (CRC), advanced adenoma (AA), benign polyp (NAA), or none of these (NEG).
[0296] Plasma was obtained using a standardized blood collection and processing protocol and then stored at -80°C until use. Written informed consent was obtained from all subjects under Institutional Review Board approval.
[0297] A description of the study cohort is provided in Table 1, which shows the number of healthy and cancer samples used for the CRC experiments in the classification models (by sex and age).
[0298] [Table 1]
[0299] The primary goal of this study was to identify serum protein biomarkers that distinguish colorectal cancer from advanced adenomas, benign disease, and healthy controls to improve the sensitivity of current biomarkers and guide clinical decisions.
[0300] Plasma was isolated from subject samples representing NEG, CRC, AA, and NAA subject populations and screened on protein arrays. A total of 1,472 features were identified between the NEG, CRC, AA, and NAA subject populations and examined for differential expression in plasma of subjects with colon cell proliferative disorders and in plasma of healthy subjects.
[0301] All protein quantification data were normalized and reported on either a relative or absolute scale.
[0302] Filtering feature values
[0303] The ability of each protein to discriminate between patients with and without a particular condition was evaluated by calculating metrics for the three groups for discrimination. The discrimination groups were disease negative vs. colorectal cancer (NEG vs. CRC), disease negative vs. advanced adenoma (NEG vs. AA), and disease negative vs. advanced and non-advanced adenoma (NEG vs. AA+NAA). Metrics calculated for this comparison included Hedges' G effect size metric, Wasserstein distance metric, feature weights in single-assay linear logistic regression with elastic net regularization, feature importance in single-assay nonlinear random forests, and feature weights in multi-assay logistic regression models.
[0304] For each protein, the percentile of the protein in each metric distribution across all proteins was calculated. Proteins were ranked by their percentile in each metric distribution. A) From protein-only analysis, had a maximum metric percentile of 95 or greater and a median metric percentile of 90 or greater B) ranked in the top 25 for maximum or median metric percentile, and C) Top 25 ranked by feature weights in a multi-assay logistic regression model. Proteins were retained for further consideration if they met at least one of the following criteria:
[0305] Several literature-derived features were also included for consideration based on an extensive literature search. Features that met the above criteria, including those from the literature, were further investigated for reagent availability and were selected from them.
[0306] FIG. 2 provides a visualization of per-protein percentiles calculated on single analyte protein data for all available targets in the protein marker dataset.
[0307] Figure 3 provides visualization of metrics from single-assay protein analysis (left panel) and multi-assay analysis (right panel). The 2.1 list consists of the intersection of proteins found when thresholding the maximum and median percentile metric distributions and intersecting that list with a list that passes the usage and performance thresholds defined by additivity. The 2.2 list consists of the intersection of proteins found when taking the top 25 proteins by rank for the maximum and median percentile metrics.
[0308] result NEG, NAA, AA, CRC Table 2 provides a list of identified proteins of the protein biomarker panel for CRC discrimination.
[0309] [Table 2]
[0310] Fold average metrics for ROC cross-validation studies. Average performance metrics were determined over the 20-fold discovery data where all data was used for feature selection, but model weights were defined within the cross-validation.
[0311] For the "target 0.9 specificity" metric, predictions were made based on the predicted probability (score) and the label. A threshold was selected that maximized sensitivity while achieving a specificity slightly above 0.9. For the "empirical" metric, predictions were made using the default prediction threshold from the classifier and by not targeting any particular specificity or based on test samples. Confidence intervals are reported in brackets and are the average of the confidence intervals per fold.
[0312] Table 3 provides classification performance specifications for the 53 features CRC versus NEG on the discovery data, where all data was used for feature selection but model weights were defined within cross-validation (there was no true holdout in this performance).
[0313] [Table 3]
[0314] Table 4 provides classification performance specifications for the 53 features AA versus NEG on the discovery data, where all data was used for feature selection but model weights were defined within cross-validation (there was no true holdout in this performance).
[0315] [Table 4]
[0316] While preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the present invention be limited by the specific examples provided herein. Although the present invention has been described with reference to the foregoing specification, the description and illustration of the embodiments herein are not meant to be construed in a limiting sense. Numerous modifications, changes, and substitutions will occur to those skilled in the art without departing from the present invention. Furthermore, it will be understood that all aspects of the present invention are not limited to the specific depictions, configurations, or relative proportions set forth herein, which depend upon a variety of conditions and variables. It will be understood that various alternatives to the embodiments of the present invention described herein may be utilized in the practice of the invention of this disclosure. It is therefore contemplated that the present invention shall cover any such alternatives, modifications, variations, or equivalents. It is intended that the following claims define the scope of the present invention, and that methods and structures within the scope of the claims and their equivalents are covered thereby.
Claims
1. A method for detecting a colon cell proliferative disorder in a subject, comprising: a) The expression level of EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein-6, mesothelin, EpCAM, ApoE in a biological sample. measuring the amount of proteins from a predetermined protein panel comprising at least six proteins selected from the group consisting of: A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, thereby providing said protein profile of said subject; b) processing said protein profile of said subject using a machine learning model trained to distinguish between subjects with said colon cell proliferative disorder and subjects without said colon cell proliferative disorder to provide an output value related to the presence or absence of said colon cell proliferative disorder, thereby indicating the presence or absence of said colon cell proliferative disorder in said subject; The method includes:
2. The method of claim 1, wherein the predetermined protein panel includes FLT3L, CEACAM5, IL-6RA, or a combination thereof.
3. The method of claim 1, wherein the predetermined protein panel includes FLT3L, CEACAM5, IL-6RA, IL-8, IL-1RT2, TNC, or a combination thereof.
4. The method of claim 1, wherein the predetermined protein panel includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, MUC-16, EGF, or a combination thereof.
5. A method according to any one of claims 1 to 4, wherein the protein profile of the subject is associated with the colon cell proliferative disorder and provides a classification of the subject having the colon cell proliferative disorder.
6. The method of any one of claims 1 to 5, wherein the biological sample from the subject is selected from the group consisting of body fluids, stool, colonic discharge, urine, plasma, serum, whole blood, isolated blood cells, cells isolated from blood, tissue biopsy, and combinations thereof.
7. The method of any one of claims 1 to 6, wherein the colon cell proliferative disorder is selected from the group consisting of adenoma (adenomatous polyp), polyposis disorder, Lynch syndrome, sessile serrated adenoma (SSA), advanced adenoma, colorectal dysplasia, colorectal adenoma, colorectal cancer, colon cancer, rectal cancer, colorectal carcinoma, colorectal adenocarcinoma, carcinoid tumor, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), lymphoma, and sarcoma.
8. A method according to any one of claims 1 to 7, wherein the machine learning model includes a classifier.
9. The method of claim 8, wherein the classifier is selected from the group consisting of a deep learning classifier, a neural network classifier, a linear discriminant analysis (LDA) classifier, a quadratic discriminant analysis (QDA) classifier, a support vector machine (SVM) classifier, a random forest (RF) classifier, a K-nearest neighbors classifier, a linear kernel support vector machine classifier, a first or second order polynomial kernel support vector machine classifier, a ridge regression classifier, an elastic net algorithm classifier, a sequential minimal problem optimization algorithm classifier, a naive Bayes algorithm classifier, and a principal component analysis classifier.
10. EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII (IL1R2), HGFR, IL-6ra, OPN, tenascin-C (TNC), thrombospondin-2 (THBS2), uPAR, CD44, kallikrein-6, mesothelin, EpCAM, Apo A predetermined panel of proteins characteristic of a colon cell proliferative disorder comprising at least six proteins selected from the group consisting of: A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125 (MUC-16), CA19-9, CA15-3 (MUC-1), and CEA.
11. The predetermined protein panel of claim 10, wherein the predetermined protein panel includes FLT3L, CEACAM5, IL-6RA, or a combination thereof.
12. The predetermined protein panel of claim 10, wherein the predetermined protein panel includes FLT3L, CEACAM5, IL-6RA, IL-8, IL-1RT2, TNC, or a combination thereof.
13. The predetermined protein panel of claim 10, wherein the predetermined protein panel includes FLT3L, CEACAM5, IL-6RA, ORM, IL-8, AGP, IL-1RT2, TNC, MUC-16, EGF, or a combination thereof.
14. A classifier configured to distinguish a population of subjects having a colon cell proliferative disorder from subjects not having said colon cell proliferative disorder, said classifier comprising: a set of measurements representing proteins from a predetermined panel of proteins characteristic of said colon cell proliferative disorder; said set of measurements being obtained from protein expression data of subjects with said colon cell proliferative disorder and subjects without said colon cell proliferative disorder; the set of measurements is used to generate a set of features corresponding to characteristics of the protein expression data, the set of features being computationally processed using a machine learning or statistical model; The machine learning or statistical model provides a feature vector useful as a classifier capable of distinguishing a population of subjects having said colon cell proliferative disorder from subjects not having said colon cell proliferative disorder.
15. A method for determining a protein profile of a biological sample from a subject, comprising: a) detecting the levels of EGF, FGF-2, FLT3L, fractalkine, IL-1a, IL-2, IL-6, IL-8, GROa, MIP-3a, complement component C2, complement component C9, factor D, factor I, MBL, MMP-2, GDF-15, osteonectin, periostin, ANGPTL4, FGF-21, FGF-23, HGF, angiopoietin-2, BMP-9, IL-1RII, HGFR, IL-6ra, OPN, tenascin-C, thrombospondin-2, uPAR, CD44, kallikrein-6, mesothelin, EpCAM, ApoE in the biological sample; measuring the amount of proteins from a predetermined protein panel comprising at least six proteins selected from the group consisting of: PSA, PSA-A1, AGP, A2MB, fetuin A, HP, L-selectin, complement component C1q, complement component C3, complement component C3b, factor B, factor H, properdin, AGRP, MMP-12, CYFRA21-1, HE4, total PSA, MIF, AFP, CA125, CA19-9, CA15-3 (MUC-1), and CEA, thereby providing said protein profile of said subject; The method includes:
